Wound dressing

Abstract
A method and apparatus are disclosed for dressing a wound. The apparatus comprises an absorbent layer for absorbing wound exudate, a liquid impermeable, gas permeable filter layer over the absorbent layer, a cover layer comprising at least one orifice and a first liquid and gas permeable transmission layer underlying the absorbent layer. The transmission layer is in fluid communication with the filter layer.
Description

The present invention relates to a method and apparatus for dressing a wound and a method for manufacturing a wound dressing. In particular, but not exclusively, the present invention relates to a wound dressing useable during topical negative pressure (TNP) therapy in which the wound dressing itself acts as a waste canister to collect and store wound exudate removed from a wound site.


There is much prior art available relating to the provision of apparatus arid methods of use thereof for the application of topical negative pressure (TNP) therapy to wounds together with other therapeutic processes intended to enhance the effects of the TNP therapy. Examples of such prior art include those listed and briefly described below.


TNP therapy assists in the closure and healing of wounds by reducing tissue oedema; encouraging blood flow and granulation of tissue; removing excess exudates and may reduce bacterial load and thus, infection to the wound. Furthermore, TNP therapy permits less outside disturbance of the wound and promotes more rapid healing.


In International patent application, WO 2004/037334, apparatus, a wound dressing and a method for aspirating, irrigating and cleansing wounds are described. In very general terms, the application describes the treatment of a wound by the application of TNP therapy for aspirating the wound together with the further provision of additional fluid for irrigating and/or cleansing the wound, which fluid, comprising both wound exudates and irrigation fluid, is then drawn off by the aspiration means and circulated through means for separating the beneficial materials therein from deleterious materials. The materials which are beneficial to wound healing are recirculated through the wound dressing and those materials deleterious to wound healing are discarded to a waste collection bag or vessel.


In International patent application, WO 2005/04670, apparatus, a wound dressing and a method for cleansing a wound using aspiration, irrigation and cleansing wounds are described. Again, in very general terms, the invention described in this document utilizes similar apparatus to that in WO 2004/037334 with regard to the aspiration, irrigation and cleansing of the wound, however, it further includes the important additional step of providing heating means to control the temperature of that beneficial material being returned to the wound site/dressing so that it is at an optimum temperature, for example, to have the most efficacious therapeutic effect on the wound.


In International patent application, WO 2005/105180, apparatus and a method for the aspiration, irrigation and/or cleansing of wounds are described. Again, in very general terms, this document describes similar apparatus to the two previously mentioned documents hereinabove but with the additional step of providing means for the supply and application of physiologically active agents to the wound site/dressing to promote wound healing.


The content of the above-noted references is included herein by reference.


However, the above described apparatus and methods are generally only applicable to a patient when hospitalised as the apparatus used is complex, needing people having specialist knowledge in how to operate and maintain the apparatus, and also relatively heavy and bulky, not being adapted for easy mobility outside of a hospital environment by a patient, for example.


Some patients having relatively less severe wounds which do not require continuous hospitalisation, for example, but whom nevertheless would benefit from the prolonged application of TNP therapy, could be treated at home or at work subject to the availability of an easily portable and maintainable TNP therapy apparatus. To this end GB-A-2 307 180 describes a portable TNP therapy unit which may be carried by a patient and clipped to belt or harness. A negative pressure can thus be applied at a wound site.


During TNP therapy a portable or non-portable therapy unit generates a negative pressure at a wound site. As fluid, including air as well as wound exudate material is removed from the wound site this must be collected in some manner remote from the wound site. With prior known therapy units ‘the collection and storage of wound exudate material is typically carried out by a waste canister connected to a pump unit of the therapy unit. The use of a canister, however, can result in the therapy unit apparatus itself being quite bulky and expensive to manufacture. Also replacing a canister or a bag in a canister in which wound exudate is collected can be a time consuming and relatively unhygienic process.


Prior known therapy units also tend to include a pump which is used to generate the negative pressure. Such pumps can be costly to manufacture and are relatively heavy.


WO 2007/030601, which is incorporated herein by reference discloses a self-contained wound dressing with a micro pump. The pump for drawing wound fluid into a vacuum zone is included in a wound dressing itself. Nevertheless wound exudate from the dressing can only be removed via a complex series of steps. The exudate removal process is also prone to contamination since once an absorbent layer is fully saturated with wound exudate an access door must be opened in the wound dressing so that the absorbent layer and micro pump can be removed. It will be appreciated that such exudate removal and pump removal can be time consuming and can lead to cross contamination between users. A further problem is that the wound dressing is prone to over expansion and rupture.


It is an aim of the present invention to at least partly mitigate the above-mentioned problems.


It is an aim of certain embodiments of the present invention to provide a method for providing negative pressure at a wound site to aid in wound closure and healing in which wound exudate drawn from a wound site during the therapy is collected and stored in a wound dressing.


It is an aim of certain embodiments of the present invention to provide a wound dressing which is able to be placed over a wound site and which includes an integrated pump to generate negative pressure at that wound site. Also for certain embodiments the wound dressing can collect any wound exudate.


According to a first aspect of the present invention there is provided apparatus for dressing a wound, comprising:

    • an absorbent layer for absorbing wound exudate;
    • a liquid impermeable, gas permeable filter layer over the absorbent layer; and a
    • cover layer comprising at least one orifice;
    • wherein the absorbent layer is in fluid communication with the filter layer.


According to a second aspect of the present invention there is provided a method of applying topical negative pressure (TNP) at a wound site, comprising the steps of:

    • pumping wound exudate and air from a wound site, a peripheral region around the wound site being sealed with a wound dressing;
    • collecting wound exudate, pumped from the wound site in an absorbent layer of the wound dressing; and
    • exhausting gas through at least one orifice in a cover layer of the wound dressing
    • and a filter layer in fluid communication with the absorbent layer.


Certain embodiments of the present invention provide the advantage that a disposable wound dressing can be fixed over a wound site and can simultaneously be used to provide negative pressure at the wound site and collect and store wound exudate.


Certain embodiments of the present invention provide the advantage that a separate therapy unit is not required to generate negative pressure at a wound site and collect and store any wound exudate. Rather a wound dressing can carry out both a pumping and wound exudate collecting process. The wound dressing may then be a one use item which can be disposed of subsequent to use. This reduces a risk of contamination.


Certain embodiments of the present invention provide the advantage that a wound dressing can be used to collect wound exudate generated during a negative pressure therapy process. A pump remote from the wound dressing can be connected to the wound dressing and reused whilst the wound dressing itself is used to collect wound exudate and may then be disposed of after use.





Embodiments of the present invention will now be described hereinafter, by way of example only, with reference to the accompanying drawings in which:



FIG. 1 illustrates a wound dressing;



FIG. 2 illustrates a top view of a wound dressing;



FIG. 3 illustrates a portion of the wound dressing;



FIG. 4 illustrates an exploded view of a wound dressing with a mounted pump; and



FIG. 5 illustrates a view of a horizontal section through a wound dressing.





In the drawings like reference numerals refer to like parts.



FIG. 1 illustrates a cross section through a wound dressing 100 according to an embodiment of the present invention. A plan view from above of the wound dressing 100 is illustrated in FIG. 2 with the line A-A indicating the location of the cross section shown in FIG. 1. It will be understood that FIG. 1 illustrates a generalised schematic view of an apparatus 100. It will be understood that embodiments of the present invention are generally applicable to use in topical negative pressure (TNP) systems. Briefly, negative pressure wound therapy assists in the closure and healing of many forms of “hard to heal” wounds by reducing tissue oedema; encouraging blood flow and granular tissue formation; removing excess exudate and reducing bacterial load (and thus infection risk). In addition, the therapy allows for less disturbance of a wound leading to more rapid healing.


The wound dressing 100 can be located over a wound site to be treated. The dressing 100 forms a sealed cavity over the wound site. Optionally wound packer can be used within a wound cavity below the dressing. Aptly the packer material can be a gauze or reticulated PU foam material.


It is envisaged that the negative pressure range for the apparatus embodying the present invention may be between about −50 mmHg and −200 mmHg (note that these pressures are relative to normal ambient atmospheric pressure thus, −200 mmHg would be about 560 mmHg in practical terms). Aptly the pressure range may be between about −75 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also aptly a pressure range of below −75 mmHg could be used. Alternatively a pressure range of over −100 mmHg could be used or over −150 mmHg.


As illustrated in FIG. 1 a lower surface 101 of the wound dressing 100 is provided by an optional wound contact layer 102. The wound contact layer 102 can be a polyurethane layer or polyethylene layer or other flexible layer which is perforated, for example via a hot pin process or in some other way, or otherwise made permeable to liquid and gas. The wound contact layer has a lower surface 101 and an upper surface 103. The perforations 104 are through holes in the wound contact layer which enables fluid to flow through the layer. The wound contact layer helps prevent tissue ingrowth into the other material of the wound dressing. The perforations are small enough to meet this requirement but still allow fluid through. The wound contact layer also helps hold the whole wound dressing together and acts as a carrier for an optional lower and upper adhesive layer (not shown). For example, a lower pressure sensitive adhesive may be provided on the underside surface 101 of the wound dressing whilst an upper pressure sensitive adhesive layer may be provided on the upper surface 103 of the wound contact layer. The pressure sensitive adhesive which may be a silicone or acrylic based adhesive or other such adhesives may be formed on both sides or optionally on a selected one or none of the sides of the wound contact layer. When a lower pressure sensitive adhesive layer is utilised this helps adhere the wound dressing to the skin around a wound site.


An optional layer 105 of porous material such as a foam layer or the like is located above the wound contact layer. This porous layer allows transmission of fluid including liquid and gas away from a wound site into upper layers of the wound dressing. The layer 105 also helps distribute pressure generated by a pump, mentioned in more detail below, so that a whole wound site sees an equalised negative pressure. Reticulated foam or a non-woven material which might be natural or synthetic can be used as the porous material of the porous layer 105.


A layer 110 of absorbent material is provided above the transmission layer 105 or where no lower transmission layer is used on the wound contact layer or where no transmission layer 105 or wound contact layer 102 are used the absorbent layer lower surface forms the wound contact layer. The absorbent material which may be a foam or non-woven natural or synthetic material and which may optionally include or be super-absorbent material forms a reservoir for fluid, particularly liquid, removed from the wound site. The material of the absorbent layer also prevents liquid collected in the wound dressing from flowing in a sloshing manner. The absorbent layer 130 also helps distribute fluid throughout the layer via a wicking action so that fluid is drawn from the wound site and stored throughout the absorbent layer. This prevents agglomeration in areas of the absorbent layer. Since in use the absorbent layer experiences negative pressures the material of the absorbent layer is chosen to absorb liquid under such circumstances. Superabsorber material is an example of such a material. Non superabsorber material can be utilised however even where significant negative pressures are envisaged. The material of the absorbent layer does not need to be hydrophilic. Aptly a material with connective open voids can be used. Aptly a material is used that can resist the compressive force of the negative pressure e.g. precompressed FT11M foam manufactured by Foam Techniques. Aptly the absorbent material is selected so that fluid is prevented from draining back out when the dressing is removed. It is to be noted that if a superabsorber is used such a material is able to expand against the compressive force of the negative pressure.


A further optional layer 112 of porous material such as a foam layer or the like is located above the absorbent layer 110. This porous layer allows transmission of fluid including liquid and gas away from a wound site into upper layers of the wound dressing. The layer 112 also helps distribute pressure generated by a pump, mentioned in more detail below, so that a whole wound site sees an equalised negative pressure. Reticulated foam or a non-woven material which might be natural or synthetic can be used as a porous material of the porous layer 112. The material may the same or different from the previously mentioned layer 105 of porous material.


A filter layer 130 is provided over the absorbent layer 110. The filter layer permits moisture vapour and gas but no liquid through. A suitable material for the filter material of the filter layer 130 is 0.2 micron Gore™ expanded PTFE from the MMT range. Larger pore sizes can also be used but these may require a secondary filter layer to ensure full bioburden containment. As wound fluid contains lipids it is preferable, though not essential, to use an oleophobic filter membrane for example 1.0 micron MMT-332 prior to 0.2 micron MMT-323. This prevents the lipids from blocking the hydrophobic filter.


It will be understood that other types of material could be used for the filter layer. More generally a microporous membrane can be used which is a thin, flat sheet of polymeric material, this contains billions of microscopic pores. Depending upon the membrane chosen these pores can range in size from 0.01 to more than 10 micrometers. Microporous membranes are available in both hydrophilic (water filtering) and hydrophobic (water repellent) forms. Aptly the wound dressing 100 according to certain embodiments of the present invention uses microporous hydrophobic membranes (MHMs). Numerous polymers may be employed to form MHMs. For example, PTFE, polypropylene, PVDF and acrylic copolymer. All of these optional polymers can be treated in order to obtain specific surface characteristics that can be both hydrophobic and oleo phobic. As such these will repel liquids with low surface tensions such as multi-vitamin infusions, lipids, surfactants, oils and organic solvents.


MHMs block liquids whilst allowing air to flow through the membranes. They are also highly efficient air filters eliminating potentially infectious aerosols and particles. A single piece of MHM is well known as an option to replace mechanical valves or vents. Incorporation of MHMs can thus reduce product assembly costs improving profits and costs/benefit ratio to a patient.


The filter layer 130 thus enables gas to be exhausted upwards through the wound dressing. Liquid, particulates and pathogens however are contained in the dressing.


A gas impermeable sealing layer 140 extends across the width of the wound dressing. The sealing layer which may, for example, be a polyurethane film having a pressure sensitive adhesive on both sides is impermeable to gas and this layer thus operates to seal a wound cavity over which the wound dressing is placed. In this way an effective chamber is made beneath the sealing layer and between the sealing layer and a wound site where a negative pressure can be established. The sealing layer 140 is sealed to the filter layer 130. For example via adhesive or welding techniques. Gas leaving the dressing thus passes through the filter layer and sealing layer.


Aptly the material of the sealing layer can have a high moisture vapour permeability for example Elastollan (Trade name) SP9109 manufactured by BASF. A dotted pattern spread acrylic adhesive can optionally be used to help improve moisture vapour permeability. An advantage of using a high moisture vapour permeability material as the sealing layer 160 is that the fluid handling capacity of the dressing may be increased significantly by the action of moisture transpiring through the film and dispersing into the atmosphere. Advantageously, transpiration rates can be easily achieved of the order of 3000 grams/meter square/24 hours as a result of the high humidity achieved in the dressing and intimate contact of material achieved during use of the apparatus at a negative pressure of up to 250 mmHg below atmospheric pressure.


As illustrated in FIG. 1 a grid array of through holes 141 are provided in the sealing layer. These enable fluid including gas and liquid to pass through the sealing layer 140. Alternatively where a separate cover layer and sealing layer are used the sealing layer may extend around only a circumferential area of the underlying layers where it seals between an outer layer (mentioned below in more detail) and the filter layer. As a result any gas leaving the wound site must leave via the filter layer. Liquid is retained in layers below the filter layer.


A layer 150 of porous material such as a foam layer or the like is located above the sealing layer 140. This porous layer allows transmission of fluid including liquid and gas away from a wound site. The layer 150 also helps distribute pressure generated by a pump, mentioned in more detail below, so that a whole wound site sees an equalised negative pressure. Reticulated foam or a non-woven material which might be natural or synthetic can be used as the porous material of the layer 150. The material may be the same or different from the material of the underlying layers 105, 112.


A cover layer 160 covers the absorbent layer of the wound dressing 100. The cover layer which, for example, may be a polyurethane film acts as a bacterial barrier and helps hold in liquid to stop fouling. The cover layer also provides integrity for the dressing and is impermeable to moisture vapour and gas. The cover layer helps hold the wound dressing together thus providing structural integrity. An upper surface 171 also presents a bacteria free non soiling surface. As an alternative the material of the cover layer can have a high moisture vapour permeability, for example Elastollan (Trade name) SP9109 manufactured by BASF. A dotted pattern spread acrylic adhesive can optionally be used to help improve moisture vapour permeability. An advantage of using a high moisture vapour permeability material as the cover layer 160 is that the fluid handling capacity of the dressing may be increased significantly by the action of moisture transpiring through the film and dispersing into the atmosphere. Advantageously, transpiration rates can be easily achieved of the order of 3000 grams/meter square/24 hours as a result of the high humidity achieved in the dressing and intimate contact of material achieved during use of the apparatus at a negative pressure of up to 250 mmHg below atmospheric pressure.


A single aperture 165 farmed as a single hole or close arrangement of holes is formed in a central region of the upper cover layer. The aperture 165 is in fluid communication with an inlet to a pump 170 which is mounted on the upper surface 171 of the cover layer. In operation the pump 170 pumps fluid through the wound dressing from a wound site below the wound contact layer 102 upwards through the first transmission layer 105, absorbent layer 110, further transmission layer 112, filter layer 130, sealing layer 140, and further transmission layer 150.


Turning to FIG. 2 which illustrates a wound dressing 100 in accordance with an embodiment of the present invention one can see the upper surface 171 of the cover layer 170 which extends radially outwardly away from a centre of the dressing into a border region 200 surrounding a central raised region 201 overlying the foam layers and layer 110 of absorber. FIG. 2 also helps illustrate the location of the pump 170 on the cover layer. As indicated in FIG. 2 the general shape of the wound dressing is a square having equal side lengths with rounded corner regions 202. It will be appreciated that wound dressings according to other embodiments of the present invention can be shaped differently such as rectangular, circular or elliptical dressings.



FIG. 3 illustrates an expanded view of the border region 200 of the wound dressing 100 illustrated in FIGS. 1, 2 and 3. As seen, the cover layer 160 extends over the foam transmission layer 150 into an edge region. Here the cover layer is secured to the sealing layer 140 and the wound contact layer 102. FIG. 3 also helps illustrate how the perforations 104 in the wound contact layer 102 extend around the foam layer 105 and absorbent layer 110. It will be noted that a space 301 is indicated in FIG. 3 underneath the sealing layer 140 and above the wound contact layer 102 and ends of the transmission layers 105, 112 and absorbent layer 110. The space 301 is shown for illustrative reasons only and in practice the transmission layers and absorbent layers will be bevelled somewhat so as to reduce the space. A further space 302 is likewise illustrated in FIG. 3 above the sealing layer and below the inner surface of the cover layer. Again this is included for illustration only and in practice these spaces will be avoided due to a nipping process in the method of manufacture. It will also be appreciated by those skilled in the art that when put in use the wound dressing will be subject to a negative pressure within a region defined by the inner surface of the cover layer. Such a negative pressure will tend to collapse any remaining spaces.


It will be understood that according to embodiments of the present invention the wound contact layer is optional. This layer is, if used, porous to water and faces an underlying wound site. A lower porous layer 105 such as a reticulated PU foam layer is used to distribute gas and fluid removal such that all areas of a wound are subjected to equal pressure. The sealing layer together with the filter layer forms a substantially liquid tight seal over the wound. Thus as the pump 170 pumps a negative pressure is generated below the sealing layer. This negative pressure is thus experienced at the target wound site. Fluid including air and wound exudate is drawn through the wound contact layer and reticulated foam layer 105. The wound exudate drawn through the lower layers of the wound dressing is dissipated and absorbed into the absorbent layer where it is collected and stored. Air and moisture vapour is drawn upwards through the wound dressing through the intermediate transmission layer 112 and through the filter layer and sealing layer. The filter layer and sealing layer are secured together so as to prevent upward movement through the wound dressing of anything other than moisture vapour and air. This air and moisture vapour is drawn upwards by the pump 170 into the fluid inlet 300. The pump exhausts the fluid as air and moisture vapour through a fluid exit (not shown).


It is to be noted that the upper transmission layer 150 and cover layer 160 are optional. Their use is helpful during multi orientation use when portions of the filter layer might otherwise become occluded. When a separate cover layer 160 is not utilised the sealing layer also performs the extra function of covering the dressing and will thus additionally act as a cover layer.


It will be appreciated by those skilled in the art that rather than have a cover layer overlying the filter layer the cover layer may itself be overlain by a filter layer. The cover layer may thus be the outermost layer of the wound dressing or the filter layer may be the outermost layer of the wound dressing. Further outer layers (not shown) may optionally be used so long as they are gas and water vapour permeable.


As still further options the dressing can contain anti-microbial e.g. nanocrystalline silver agents on the wound contact layer and/or silver sulphur diazine in the absorbent layer. These may be used separately or together. These respectively kill micro-organisms in the wound and micro-organisms in the absorption matrix. As a still further option other active components, for example, pain suppressants, such as ibuprofen, may be included. Also agents which enhance cell activity, such as growth factors or that inhibit enzymes, such as matrix metalloproteinase inhibitors, such as tissue inhibitors of metalloproteinase (TIMPS) or zinc chelators could be utilised. As a still further option odour trapping elements such as activated carbon, cyclodextrine, zealite or the like may be included in the absorbent layer or as a still further layer above the filter layer.



FIG. 4 illustrates an exploded view of the wound dressing illustrated in FIGS. 1, 2 and 3. As illustrated in FIG. 4 the lower-most layer of the wound dressing is a perforated wound contact layer 102. It will be appreciated that prior to use a still lower protective layer may be secured to the lower surface 101 of the wound contact layer. The protective paper (not shown) is removed immediately prior to application of the wound dressing over a wound site. During manufacture a central region 400 of the wound contact layer 102 is made slightly concave so as to provide a dished upper surface 103 for the wound contact layer.


A transmission layer 105 is duly located in the dished central region 400 of the wound contact layer. The foam layer includes a substantially rectangular base region 401 together with an array of upstanding columns 402. As illustrated in FIG. 4 an array of 8×8 columns 402 may be used. It will be appreciated that other numbers of columns may be utilised. The columns 402 have a substantially circular cross section although it will be appreciated that column elements having different cross section shapes could be used. The column elements 402 and base section 402 are aptly integrally formed although these could be separately formed with the column elements being secured to the base section in some appropriate way such as via adhesive techniques.


The absorbent layer 110 is located above the transmission layer 105. The absorbent layer 110 is a layer of absorbent material and includes through holes 403 formed in a substantially rectangular block 404 of absorbent material. The through holes are set out in an 8×8 array to coincide with the upstanding columns 402 in the underlying transmission layer. It will be appreciated that the number and pattern of through bores 403 is selected to tally with the shape and number and arrangement of the columns.


The intermediate transmission layer 112 is a substantially rectangular base section 405 of porous material such as reticulated foam with an array of columns 406 extending downwardly from a lower surface of the base 405. The columns 406 coincide with locations of the through bores 403 in the absorbent layer. It will be appreciated that the columns 406 of the intermediate transmission layer 112 may be integrally formed with the base portion 405 of the transmission layer or may be secured in some fashion thereto. The height of the columns 402,406 of the lower and intermediate transmission layers respectively is such that an upper contact surface of the columns 402 of the lower transmission layer and a lower contact surface of the columns 406 of the intermediate transmission layer contact when the wound dressing is put together. These thus provide fluid transmission paths through the absorber layer so that fluid, including air and wound exudate and liquid, is drawn from the lower region upwardly through the absorbent layer when the pump 170 is operating.


A rectangular layer of filter material 130 is located above the upper surface of the base section 405 of the intermediate transmission layer. The filter layer blocks movement therethrough of liquid. The filter layer is aptly a 0.2 micron Gore™ expanded PTFE sheet.


A sealing layer 140 is located over the filter layer 130. The sealing layer has a border region and a generally concave central region 407. The underside of the sealing layer 140 is thus recessed. An array of apertures set out in a 5×5 grid array is made through the sealing layer 140. The sealing layer away from the apertures is gas and fluid tight. If a material having a high moisture vapour permeability is optionally used then the sealing layer will of course be permeable to moisture vapour. Fluid, including liquid and gas, can of course penetrate through the perforations. The filter layer 130 which is secured on the underside of the sealing layer, however, prevents liquid penetration through the apertures and to an extent prevents penetration of air through the apertures. Moisture vapour can penetrate through the apertures.


An upper transmission layer formed as a sheet of reticulated foam is located over the central region of the upper surface of the sealing layer 140. The upper transmission layer acts as a manifold and diffuser to help spread the negative pressure generated by the pump 170.


A cover layer 160 is located over the sealing layer and upper transmission layer 150. The cover layer has a border region 200 and a central raised region 201. The underside of the cover layer thus presents a central dished region to receive the upper transmission layer, raised central region of the sealing layer and the filter layer, intermediate transmission layer, absorbent layer and lower transmission layer. A central aperture 165 is made in the centre of the upper surface of the cover layer. The central aperture 165 is located to coincide with a fluid inlet 300 of the pump 170. Thus in use when a pump 170 is in use a negative pressure is generated under the cover 160. This negative pressure is distributed throughout the wound dressing and at a target wound site located under the wound contact layer. As the negative pressure is established and maintained wound exudate and air is drawn upwards away from the wound site through the wound dressing. Liquid and air is drawn upwards through the wound contact layer into the base of the lower transmission layer 105 and upwards through the connecting columns in the lower transmission layer and intermediate transmission layer. It will be appreciated of course that columns having a height sufficient to bridge the whole of the absorbent layer could be provided on either the upper surface of the lower transmission layer 105 or the lower surface of the intermediate transmission layer 112. Alternatively the apertures 403 in the absorbent layer may be filled with transmissive material such as foam cylinders when the wound dressing is manufactured. Any wound exudate being drawn upward through the wound dressing is dissipated outwardly from the absorbent material in the aperture regions of the absorbent layer. The liquid is thus collected and stored in the absorbent layer. Air and moisture vapour carries on upwards through the filter layer 130 and sealing layer 140 and is evacuated by the pump 170.



FIG. 5 illustrates a horizontal cross section through the wound dressing illustrating an upper surface 404 of the absorbent layer including apertures 403. Each of the apertures 403 is filled with absorbent material such as columns 402 from the lower intermediate layer.


It will be appreciated that according to certain embodiments of the present invention fluid communication paths through which fluid can be transmitted from the lower transmission layer to the intermediate transmission layer can be made by pinching together peripheral regions of the lower and intermediate regions. Fluid transmission would thus proceed around the peripheral edges of the wound dressing. Such fluid paths may replace the fluid paths formed by the columns passing through apertures in the absorbent layer or may alternatively take the place of such passageways. This would maximise the quantity of absorber material in the layer 110 in the resultant wound dressing.


It is to be noted that according to certain other embodiments of the present invention a remote pump may be mounted to a border region of the wound dressing rather than onto the top surface. In such case tubes may be connected directly to the pump. Subsequent to a single use the wound dressing and pump may thus be discarded. As an option the tubes may be provided with a click fit connector or other easy fit connector which can be connected to corresponding mating connectors joined via corresponding tubes to a remote pump. In this way a remote pump may be reused whilst the wound dressing itself including connecting tubes and connectors is disposable after a single use.


It will be appreciated that alternatively the tubes could be provided by a single dual lumen tube. As a still further alternative the tubes may be provided by a single continuous looped tube, the tube then passing through pinch rollers for a peristaltic pump.


It will be understood that for embodiments of the present invention which include a pump mounted on the cover layer or on a peripheral border area of the dressing an integral power source and control circuitry can be included. Alternatively the power source can be external to the pump and remotely mounted. A remote power source and/or control circuitry improves the disposability of the dressing and permits battery recharge if spare batteries are used.


It is to be noted that in use the dressing may be used “up-side down”, at an angle or vertical. References to upper and lower are thus used for explanation purposes only.


Where a separate cover layer and sealing layer are utilised such layers may be manufactured from the same or different materials.


Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.


Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.


Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.

Claims
  • 1. A method for treating a tissue site with reduced pressure, the method comprising: positioning a porous member proximate to the tissue site;covering the porous member with a sealing layer having at least one aperture to form a sealed space over the porous member and the sealing layer comprising a dotted pattern spread adhesive;maintaining reduced pressure under the sealing layer within the sealed space; andtranspiring moisture from the sealed space through the sealing layer into the atmosphere while reduced pressure is maintained under the sealing layer within the sealed space, wherein the sealing layer transpires moisture at a rate of at least about 3000 grams/meter square/24 hours;wherein the dotted pattern spread adhesive is spread across the sealing layer in a manner to improve moisture vapor permeability and the transpiration of moisture to the atmosphere compared to a sealing layer fully covered with adhesive.
  • 2. The method of claim 1, wherein moisture vapour penetrates through the at least one aperture.
  • 3. The method of claim 1, wherein the at least one aperture in the sealing layer is covered by a liquid impermeable membrane.
  • 4. The method of claim 1, wherein the sealing layer is made of a moisture vapour permeability material.
  • 5. The method of claim 1, further comprising maintaining a pressure differential across the sealing layer when reduced pressure is maintained within the sealed space.
  • 6. The method of claim 1, further comprising positioning a non-woven absorbent material in the sealed space.
  • 7. The method of claim 1, wherein the adhesive comprises a pressure-sensitive adhesive.
  • 8. A method of manufacturing a dressing for treating a tissue site, the method comprising: providing a porous member for placing proximate to the tissue site;providing a sealing layer having at least one aperture and comprising a dotted pattern spread adhesive, wherein the sealing layer is configured to transpire moisture at a rate of at least about 3000 grams/meter square/24 hours while maintaining a reduced pressure under the sealing layer; andsecuring a membrane relative to the sealing layer to cover the at least one aperture, wherein the membrane is configured to permit penetration of moisture vapour through the sealing layer;wherein the dotted pattern spread adhesive is spread across the sealing layer in a manner to improve moisture vapor permeability and the transpiration of moisture to the atmosphere compared to a sealing layer fully covered with adhesive.
  • 9. The method of claim 8, wherein the moisture vapour penetrates through the at least one aperture in the sealing layer.
  • 10. The method of claim 8, wherein the sealing layer is made of a moisture vapour permeability material configured to transpire moisture from within the dressing into the atmosphere.
  • 11. The method of claim 8, further comprising providing a non-woven absorbent material between the porous member and the sealing layer.
  • 12. The method of claim 8, wherein the adhesive comprises a pressure-sensitive adhesive.
  • 13. A dressing for treating a tissue site with reduced pressure, the dressing comprising: a porous member configured to be positioned proximate to the tissue site; anda sealing layer configured to form a sealed space over the porous member and maintain reduced pressure under the sealing layer within the sealed space, the sealing layer having at least one aperture and being configured to transpire moisture from the sealed space through the sealing layer into the atmosphere, wherein the sealing layer is configured to transpire moisture at a rate of at least about 3000 grams/meter square/24 hours; andwherein the sealing layer comprises a dotted pattern spread adhesive and wherein the dotted pattern spread adhesive is spread across the sealing layer in a manner to improve moisture vapor permeability and the transpiration of moisture to the atmosphere compared to a sealing layer fully covered with adhesive.
  • 14. The dressing of claim 13, wherein the sealing layer is configured to maintain a pressure differential across the sealing layer when reduced pressure is maintained within the sealed space.
  • 15. The dressing of claim 13, wherein the dressing further comprises a non-woven absorbent material.
  • 16. The dressing of claim 13, wherein the adhesive comprises a pressure-sensitive adhesive.
Priority Claims (2)
Number Date Country Kind
0722820 Nov 2007 GB national
0817020 Sep 2008 GB national
Parent Case Info

This application is a continuation of U.S. application Ser. No. 14/869,826, filed Sep. 29, 2015, which is a continuation of U.S. application Ser. No. 14/259,026, filed Apr. 22, 2014, which is a continuation of U.S. application Ser. No. 12/744,277, filed Sep. 20, 2010, now U.S. Pat. No. 8,764,732, which is the U.S. National Phase of PCT International Application No. PCT/GB2008/051090 filed on Nov. 20, 2008, designating the United States and published on May 28, 2009 as WO 2009/066106, which claims priority to Great Britain Patent Application No. 0722820.8, filed Nov. 21, 2007, and Great Britain Patent Application No. 0817020.1, filed Sep. 17, 2008. The disclosure of these prior applications are incorporated by reference in their entireties and should be considered a part of this specification.

US Referenced Citations (992)
Number Name Date Kind
695270 Beringer Mar 1902 A
1480562 Mock Jan 1924 A
2280915 Johnson Apr 1942 A
2367690 Purdy Jul 1943 A
2568933 Robbins Sep 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2910763 Lauterbach Aug 1955 A
3115138 McElvenny et al. Dec 1963 A
3367332 Groves Feb 1968 A
3572340 Lloyd et al. Mar 1971 A
3874387 Barbieri Apr 1975 A
3972328 Chen Aug 1976 A
3993080 Loseff Nov 1976 A
4029598 Neisius et al. Jun 1977 A
RE29319 Nordby et al. Jul 1977 E
4102342 Akiyama et al. Jul 1978 A
4112947 Nehring Sep 1978 A
4117551 Books et al. Sep 1978 A
4136696 Nehring Jan 1979 A
4184510 Murry et al. Jan 1980 A
4217894 Franetzki Aug 1980 A
4219019 Coates Aug 1980 A
4224941 Stivala Sep 1980 A
4224945 Cohen Sep 1980 A
4316466 Babb Feb 1982 A
4382441 Svedman May 1983 A
4398910 Blake et al. Aug 1983 A
4465485 Kashmer et al. Aug 1984 A
4466431 Tharrat et al. Aug 1984 A
4529402 Weilbacher et al. Jul 1985 A
4534356 Papadakis Aug 1985 A
4538920 Drake et al. Sep 1985 A
4569674 Phillips Feb 1986 A
4573965 Russo Mar 1986 A
4608041 Nielsen Aug 1986 A
4624656 Clark et al. Nov 1986 A
4655754 Richmond et al. Apr 1987 A
4655766 Theeuwes et al. Apr 1987 A
4681562 Beck et al. Jul 1987 A
4710165 McNeil et al. Dec 1987 A
4728499 Fehder Mar 1988 A
4753536 Spehar et al. Jun 1988 A
4767026 Keller Aug 1988 A
4767943 Adler et al. Aug 1988 A
4771919 Ernst Sep 1988 A
4778446 Jensen Oct 1988 A
4792328 Beck et al. Dec 1988 A
4813942 Alvarez Mar 1989 A
4826494 Richmond et al. May 1989 A
4828546 McNeil et al. May 1989 A
4872450 Austad Oct 1989 A
4921488 Maitz et al. May 1990 A
4936834 Beck et al. Jun 1990 A
4969880 Zamierowski Nov 1990 A
4972829 Knerr Nov 1990 A
4979944 Luzsicza Dec 1990 A
4994022 Steffi et al. Feb 1991 A
5010115 Grisoni Apr 1991 A
5055195 Trasch et al. Oct 1991 A
5055198 Shettigar Oct 1991 A
5056510 Gilman Oct 1991 A
5060642 Gilman Oct 1991 A
5061258 Martz Oct 1991 A
5064653 Sessions et al. Nov 1991 A
5073172 Fell Dec 1991 A
5080493 McKown et al. Jan 1992 A
5100396 Zamierowski Mar 1992 A
5134994 Say Aug 1992 A
5152757 Eriksson Oct 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5181905 Flam Jan 1993 A
5215519 Shettigar Jun 1993 A
5222714 Morinigo et al. Jun 1993 A
5234419 Bryant et al. Aug 1993 A
5238732 Krishnan Aug 1993 A
5249709 Duckworth et al. Oct 1993 A
5261893 Zamierowski Nov 1993 A
5266326 Barry et al. Nov 1993 A
5266928 Johnson Nov 1993 A
5279608 Cherif Cheikh Jan 1994 A
5291822 Alsobrooks et al. Mar 1994 A
5328614 Matsumura Jul 1994 A
5333760 Simmen et al. Aug 1994 A
5349896 Connelly et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5380280 Peterson Jan 1995 A
D357743 Bilitz et al. Apr 1995 S
5417743 Dauber May 1995 A
5437651 Todd et al. Aug 1995 A
5445604 Lang Aug 1995 A
5449003 Sugimura Sep 1995 A
5449347 Preen et al. Sep 1995 A
5456745 Rorefer et al. Oct 1995 A
5466229 Elson Nov 1995 A
5489280 Russell Feb 1996 A
5498338 Kruger et al. Mar 1996 A
5527293 Zamierowski Jun 1996 A
5536233 Khouri Jul 1996 A
5549584 Gross Aug 1996 A
5582596 Fukunaga et al. Dec 1996 A
5583114 Barrows et al. Dec 1996 A
5609271 Keller et al. Mar 1997 A
5612050 Rowe et al. Mar 1997 A
5624423 Anjur et al. Apr 1997 A
5632731 Patel May 1997 A
5634391 Eady Jun 1997 A
5636643 Argenta et al. Jun 1997 A
5643189 Masini Jul 1997 A
5645081 Argenta et al. Jul 1997 A
5660823 Chakrabarti et al. Aug 1997 A
5662583 Khouri Sep 1997 A
5676525 Berner et al. Oct 1997 A
5676634 Khouri Oct 1997 A
5678564 Lawrence et al. Oct 1997 A
5687633 Eady Nov 1997 A
5693013 Geuder Dec 1997 A
5695445 Khouri Dec 1997 A
5700477 Rosenthal et al. Dec 1997 A
5701917 Khouri Dec 1997 A
5707499 Joshi et al. Jan 1998 A
5717030 Dunn et al. Feb 1998 A
5730587 Snyder et al. Mar 1998 A
5733337 Carr et al. Mar 1998 A
5743170 Forman et al. Apr 1998 A
5747064 Burnett et al. May 1998 A
5759570 Arnold Jun 1998 A
5769608 Seale Jun 1998 A
5776098 Silver et al. Jul 1998 A
5776193 Kwan et al. Jul 1998 A
5779657 Daneshvar Jul 1998 A
5785508 Bolt Jul 1998 A
5785688 Joshi et al. Jul 1998 A
5817145 Augustine et al. Oct 1998 A
5830496 Freeman Nov 1998 A
5833646 Masini Nov 1998 A
5834007 Kubota Nov 1998 A
5843011 Lucas Dec 1998 A
5852126 Barnard et al. Dec 1998 A
5863184 Juterbock et al. Jan 1999 A
5868933 Patrick et al. Feb 1999 A
5874500 Rhee et al. Feb 1999 A
5876611 Shettigar Mar 1999 A
5897296 Yamamoto et al. Apr 1999 A
5902256 Benaron May 1999 A
5902260 Gilman May 1999 A
5904659 Duarte May 1999 A
5928265 Fleischmann Jul 1999 A
5941840 Court et al. Aug 1999 A
5945115 Dunn et al. Aug 1999 A
5950523 Reynolds Sep 1999 A
5962010 Greff et al. Oct 1999 A
5964723 Augustine Oct 1999 A
5998472 Berger et al. Dec 1999 A
6010527 Augustine et al. Jan 2000 A
6013097 Augustine et al. Jan 2000 A
6068588 Goldowsky May 2000 A
6071267 Zamierowski Jun 2000 A
6080685 Eady Jun 2000 A
6093160 Augustine et al. Jul 2000 A
6102680 Fraser et al. Aug 2000 A
6103951 Freeman Aug 2000 A
6110197 Augustine et al. Aug 2000 A
6117111 Fleischmann Sep 2000 A
6135116 Vogel et al. Oct 2000 A
6138550 Fingar, Jr. Oct 2000 A
6142982 Hunt et al. Nov 2000 A
6143352 Clark et al. Nov 2000 A
6145430 Able et al. Nov 2000 A
6158327 Huss Dec 2000 A
6162194 Shipp Dec 2000 A
6165201 Sawhney et al. Dec 2000 A
6168788 Wortham Jan 2001 B1
6168800 Dobos et al. Jan 2001 B1
6176307 Danos et al. Jan 2001 B1
6183438 Berguer Feb 2001 B1
6214332 Askill et al. Apr 2001 B1
6225523 Masini May 2001 B1
6227825 Vay May 2001 B1
6230609 Fingar May 2001 B1
6231310 Tojo et al. May 2001 B1
6248084 Augustine et al. Jun 2001 B1
6249198 Clark et al. Jun 2001 B1
6252129 Coffee Jun 2001 B1
6254567 Treu et al. Jul 2001 B1
6255552 Cummings et al. Jul 2001 B1
6257847 Silver et al. Jul 2001 B1
6261276 Reitsma Jul 2001 B1
6261283 Morgan et al. Jul 2001 B1
6267740 Augustine et al. Jul 2001 B1
6287521 Quay et al. Sep 2001 B1
6291050 Cree et al. Sep 2001 B1
6293917 Augustine et al. Sep 2001 B1
6323568 Zabar Nov 2001 B1
6327960 Heimueller et al. Dec 2001 B1
6343539 Du Feb 2002 B1
6345623 Heaton et al. Feb 2002 B1
6383163 Kelly et al. May 2002 B1
6391294 Dettmar et al. May 2002 B1
6398761 Bills et al. Jun 2002 B1
6398767 Fleischmann Jun 2002 B1
6402724 Smith et al. Jun 2002 B1
6413057 Hong et al. Jul 2002 B1
6440167 Shimizu Aug 2002 B2
6447802 Sessions et al. Sep 2002 B2
6450773 Upton Sep 2002 B1
6458109 Henley et al. Oct 2002 B1
6465708 Augustine Oct 2002 B1
6468295 Augustine et al. Oct 2002 B2
6471685 Johnson Oct 2002 B1
6471982 Lydon et al. Oct 2002 B1
6481986 Silver et al. Nov 2002 B1
6486285 Fujita Nov 2002 B2
6491684 Joshi et al. Dec 2002 B1
6495127 Wallace et al. Dec 2002 B1
6500112 Khouri Dec 2002 B1
6509031 Miller et al. Jan 2003 B1
6521251 Askill et al. Feb 2003 B2
6540490 Lilie Apr 2003 B1
6547467 Quintero Apr 2003 B2
6547756 Greter et al. Apr 2003 B1
6553998 Heaton et al. Apr 2003 B2
6575940 Levinson et al. Jun 2003 B1
6580012 Augustine et al. Jun 2003 B1
6589028 Eckerbom et al. Jul 2003 B1
6596704 Court et al. Jul 2003 B1
6599262 Masini Jul 2003 B1
6607495 Skalak et al. Aug 2003 B1
6626891 Ohmstede Sep 2003 B2
6627216 Brandt et al. Sep 2003 B2
6629774 Guruendeman Oct 2003 B1
6638035 Puff Oct 2003 B1
6638270 Johnson Oct 2003 B2
6648862 Watson Nov 2003 B2
6655257 Meyer Dec 2003 B1
6673028 Argenta et al. Jan 2004 B1
6673036 Britto Jan 2004 B1
6676610 Morton et al. Jan 2004 B2
6676631 Grefer Jan 2004 B1
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6695824 Howard et al. Feb 2004 B2
6699213 Annis et al. Mar 2004 B1
6730299 Tayot et al. May 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6767334 Randolph Jul 2004 B1
6775807 Lowther et al. Aug 2004 B2
6787682 Gilman Sep 2004 B2
6790438 Constancis et al. Sep 2004 B1
6794554 Sessions et al. Sep 2004 B2
6800074 Henley et al. Oct 2004 B2
6808517 Greter et al. Oct 2004 B2
6814079 Heaton et al. Nov 2004 B2
6823905 Smith et al. Nov 2004 B1
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6936037 Bubb et al. Aug 2005 B2
6942633 Odland Sep 2005 B2
6951553 Bubb et al. Oct 2005 B2
6960179 Gura Nov 2005 B2
6977323 Swenson Dec 2005 B1
6979324 Bybordi et al. Dec 2005 B2
6987209 Augustine et al. Jan 2006 B2
6994702 Johnson Feb 2006 B1
6997897 Silver et al. Feb 2006 B1
7004915 Boynton et al. Feb 2006 B2
7008400 Silver et al. Mar 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7041057 Faupel et al. May 2006 B1
7067709 Murate et al. Jun 2006 B2
7070584 Johnson et al. Jul 2006 B2
7077832 Fleischmann Jul 2006 B2
7087806 Scheinberg et al. Aug 2006 B2
7108683 Zamierowski Sep 2006 B2
7117869 Heaton et al. Oct 2006 B2
7122046 Augustine et al. Oct 2006 B2
7128735 Weston Oct 2006 B2
7129210 Lowinger et al. Oct 2006 B2
7141714 Nielsen Nov 2006 B2
7151348 Ueda et al. Dec 2006 B1
7182085 Larsen Feb 2007 B1
7195624 Lockwood Mar 2007 B2
7198046 Argenta et al. Apr 2007 B1
7214202 Vogel et al. May 2007 B1
7216651 Argenta et al. May 2007 B2
7220889 Sigurjonsson et al. May 2007 B2
7238850 Shimanuki Jul 2007 B2
7255681 Silver et al. Aug 2007 B1
7273054 Heaton et al. Sep 2007 B2
7279612 Heaton et al. Oct 2007 B1
7303757 Schankereli et al. Dec 2007 B2
7316672 Hunt et al. Jan 2008 B1
7335809 Riesinger Feb 2008 B2
7338482 Lockwood et al. Mar 2008 B2
7361184 Joshi Apr 2008 B2
7381211 Zamierowski Jun 2008 B2
7381859 Hunt et al. Jun 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7447327 Kitamura et al. Nov 2008 B2
7470830 Sigurjonsson et al. Dec 2008 B2
7485112 Karpowicz et al. Feb 2009 B2
7494482 Orgill et al. Feb 2009 B2
7503910 Adahan Mar 2009 B2
7507870 Nielsen et al. Mar 2009 B2
7524286 Johnson Apr 2009 B2
7524315 Blott et al. Apr 2009 B2
7534240 Johnson May 2009 B1
7534927 Lockwood May 2009 B2
7553306 Hunt et al. Jun 2009 B1
7569742 Haggstrom et al. Aug 2009 B2
7601129 Aali Oct 2009 B2
7605298 Bechert et al. Oct 2009 B2
7611500 Lina et al. Nov 2009 B1
7612247 Oyaski Nov 2009 B2
7615036 Joshi et al. Nov 2009 B2
7622629 Aail Nov 2009 B2
D605775 Koch et al. Dec 2009 S
7625362 Boehringer et al. Dec 2009 B2
D608007 Arbesman et al. Jan 2010 S
7645253 Gura et al. Jan 2010 B2
7645269 Zamierowski Jan 2010 B2
7670323 Hunt et al. Mar 2010 B2
7678090 Risk, Jr. Mar 2010 B2
7687678 Jacobs Mar 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7699830 Martin Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7717313 Criscuolo et al. May 2010 B2
7718249 Russell et al. May 2010 B2
7722582 Lina et al. May 2010 B2
7731702 Bybordi et al. Jun 2010 B2
7745681 Ferguson Jun 2010 B1
7749531 Booher Jul 2010 B2
7753894 Blott et al. Jul 2010 B2
7754936 Heaton et al. Jul 2010 B2
7754937 Boehringer et al. Jul 2010 B2
7758514 Grigoryants et al. Jul 2010 B2
7758554 Lina et al. Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759538 Fleischmann Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7763000 Risk, Jr. et al. Jul 2010 B2
7763769 Johnson et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7776028 Miller et al. Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7790945 Watson, Jr. Sep 2010 B1
7790946 Mulligan Sep 2010 B2
7794438 Henley et al. Sep 2010 B2
7794450 Blott et al. Sep 2010 B2
7803980 Griffiths et al. Sep 2010 B2
7811269 Boynton et al. Oct 2010 B2
7815616 Boehringer et al. Oct 2010 B2
7816577 Aali Oct 2010 B2
7828782 Suzuki Nov 2010 B2
7838716 de Luis et al. Nov 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7846141 Weston Dec 2010 B2
7857806 Karpowicz et al. Dec 2010 B2
7858838 Holm et al. Dec 2010 B2
7862339 Mulligan Jan 2011 B2
7862831 Wang et al. Jan 2011 B2
7867206 Lockwood et al. Jan 2011 B2
7880050 Robinson et al. Feb 2011 B2
7884258 Boehringer et al. Feb 2011 B2
7886746 Heaton et al. Feb 2011 B2
7896823 Mangrum et al. Mar 2011 B2
7896856 Petrosenko et al. Mar 2011 B2
7896864 Lockwood et al. Mar 2011 B2
7909805 Weston Mar 2011 B2
7910135 St. John et al. Mar 2011 B2
7910791 Coffey Mar 2011 B2
7922676 Daskal et al. Apr 2011 B2
7922703 Riesinger Apr 2011 B2
7927318 Risk, Jr. et al. Apr 2011 B2
7931630 Nishtala et al. Apr 2011 B2
7942866 Radi et al. May 2011 B2
7951100 Hunt et al. May 2011 B2
7951124 Boehringer et al. May 2011 B2
7959624 Riesinger Jun 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
D642594 Mattson et al. Aug 2011 S
7988680 Lockwood et al. Aug 2011 B2
7998125 Weston Aug 2011 B2
8007164 Miyano et al. Aug 2011 B2
8007257 Heaton et al. Aug 2011 B2
8007481 Schuessler et al. Aug 2011 B2
8021348 Risk, Jr. et al. Sep 2011 B2
8022266 Boehringer et al. Sep 2011 B2
8025650 Anderson et al. Sep 2011 B2
8034037 Adams et al. Oct 2011 B2
8062272 Weston Nov 2011 B2
8062273 Weston Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8084663 Watson, Jr. Dec 2011 B2
8092441 Sugito Jan 2012 B2
8097272 Addison Jan 2012 B2
8100887 Weston et al. Jan 2012 B2
8105295 Blott et al. Jan 2012 B2
8118794 Weston et al. Feb 2012 B2
8119160 Looney et al. Feb 2012 B2
8133211 Cavanaugh, II et al. Mar 2012 B2
8152785 Vitaris Apr 2012 B2
8158844 McNeil Apr 2012 B2
8162907 Heagle Apr 2012 B2
8162909 Blott et al. Apr 2012 B2
8168848 Lockwood et al. May 2012 B2
8192409 Hardman et al. Jun 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8211071 Mormino et al. Jul 2012 B2
8212100 Moore Jul 2012 B2
8215929 Shen et al. Jul 2012 B2
8226942 Charier et al. Jul 2012 B2
8235955 Blott et al. Aug 2012 B2
8235972 Adahan Aug 2012 B2
8241015 Lillie Aug 2012 B2
8241261 Randolph et al. Aug 2012 B2
8246606 Stevenson et al. Aug 2012 B2
8251979 Malhi Aug 2012 B2
8257327 Blott et al. Sep 2012 B2
8257328 Augustine et al. Sep 2012 B2
8267908 Coulthard Sep 2012 B2
8267918 Johnson et al. Sep 2012 B2
8273368 Ambrosio et al. Sep 2012 B2
8282611 Weston Oct 2012 B2
8294586 Pidgeon et al. Oct 2012 B2
8303552 Weston Nov 2012 B2
8308714 Weston et al. Nov 2012 B2
8317774 Adahan Nov 2012 B2
8323264 Weston et al. Dec 2012 B2
8338402 Fry et al. Dec 2012 B2
8348910 Blott et al. Jan 2013 B2
8372049 Jaeb et al. Feb 2013 B2
8372050 Jaeb et al. Feb 2013 B2
8376972 Fleischmann Feb 2013 B2
8382731 Johannison Feb 2013 B2
8404921 Lee et al. Mar 2013 B2
D679819 Peron Apr 2013 S
D679820 Peron Apr 2013 S
8410189 Carnahan et al. Apr 2013 B2
8414519 Hudspeth et al. Apr 2013 B2
8419696 Wilkes Apr 2013 B2
8425478 Olson Apr 2013 B2
8444612 Patel et al. May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8494349 Gordon Jul 2013 B2
8506554 Adahan Aug 2013 B2
8529548 Blott et al. Sep 2013 B2
8535283 Heaton et al. Sep 2013 B2
8535296 Blott et al. Sep 2013 B2
8545464 Weston Oct 2013 B2
8545466 Andresen et al. Oct 2013 B2
8556871 Mormino et al. Oct 2013 B2
8569566 Blott et al. Oct 2013 B2
8603074 Kagan Dec 2013 B2
8617129 Hartwell Dec 2013 B2
8622981 Hartwell et al. Jan 2014 B2
8628505 Weston Jan 2014 B2
8641691 Fink Feb 2014 B2
8663198 Buan et al. Mar 2014 B2
8679079 Heaton et al. Mar 2014 B2
8715256 Greener May 2014 B2
8753670 Delmotte Jun 2014 B2
8764732 Hartwell Jul 2014 B2
8795243 Weston Aug 2014 B2
8795244 Randolph et al. Aug 2014 B2
8795635 Tamarkin et al. Aug 2014 B2
8795713 Makower et al. Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8814842 Coulthard et al. Aug 2014 B2
8827983 Braga et al. Sep 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
8834451 Blott et al. Sep 2014 B2
8834452 Hudspeth et al. Sep 2014 B2
8843327 Vernon-Harcourt et al. Sep 2014 B2
8864748 Coulthard et al. Oct 2014 B2
8905985 Allen et al. Dec 2014 B2
8915895 Jaeb et al. Dec 2014 B2
8945074 Buan et al. Feb 2015 B2
8956336 Haggstrom et al. Feb 2015 B2
8968773 Thomas et al. Mar 2015 B2
8974429 Gordon et al. Mar 2015 B2
9012714 Fleischmann Apr 2015 B2
9028872 Gaserod et al. May 2015 B2
9033942 Vess May 2015 B2
9044579 Blott et al. Jun 2015 B2
9050209 Coulthard et al. Jun 2015 B2
9061095 Adie et al. Jun 2015 B2
9084845 Adie et al. Jul 2015 B2
9127665 Locke et al. Sep 2015 B2
9168330 Joshi et al. Oct 2015 B2
9198802 Robinson et al. Dec 2015 B2
9199012 Vitaris et al. Dec 2015 B2
9211365 Weston Dec 2015 B2
9220822 Hartwell et al. Dec 2015 B2
9302033 Riesinger Apr 2016 B2
9375353 Vitaris et al. Jun 2016 B2
9375521 Hudspeth et al. Jun 2016 B2
9381283 Adams et al. Jul 2016 B2
9414968 Heagle Aug 2016 B2
9421133 Hu et al. Aug 2016 B2
9446178 Blott et al. Sep 2016 B2
9452245 Jaeb et al. Sep 2016 B2
9452248 Blott et al. Sep 2016 B2
9456928 Haggstrom et al. Oct 2016 B2
9669138 Joshi et al. Jun 2017 B2
9795725 Joshi et al. Oct 2017 B2
9844475 Hartwell Dec 2017 B2
10010656 Jaeb et al. Jul 2018 B2
10123909 Hartwell Nov 2018 B2
10265445 Weston Apr 2019 B2
10384041 Patel et al. Aug 2019 B2
10391212 Joshi et al. Aug 2019 B2
10463773 Haggstrom et al. Nov 2019 B2
20010001278 Drevet May 2001 A1
20010004082 Keller et al. Jun 2001 A1
20010031911 Khouri Oct 2001 A1
20010033795 Humpheries Oct 2001 A1
20010034499 Sessions et al. Oct 2001 A1
20010038799 Silver et al. Nov 2001 A1
20010043870 Song Nov 2001 A1
20010043913 Spaans et al. Nov 2001 A1
20010043943 Coffey Nov 2001 A1
20020002209 Mork Jan 2002 A1
20020017304 Heaton et al. Feb 2002 A1
20020026133 Augustine et al. Feb 2002 A1
20020026946 McKay Mar 2002 A1
20020038826 Hurray et al. Apr 2002 A1
20020082567 Lockwood et al. Jun 2002 A1
20020122732 Oh et al. Sep 2002 A1
20020122771 Holland et al. Sep 2002 A1
20020138036 Babaev Sep 2002 A1
20020143286 Tumey Oct 2002 A1
20020145007 Sawhney et al. Oct 2002 A1
20020161317 Risk et al. Oct 2002 A1
20020164255 Burr et al. Nov 2002 A1
20020183702 Henley et al. Dec 2002 A1
20020187182 Kramer et al. Dec 2002 A1
20020198490 Wirt et al. Dec 2002 A1
20020198504 Risk et al. Dec 2002 A1
20030021775 Freeman Jan 2003 A1
20030023286 Augustine et al. Jan 2003 A1
20030035743 Lee et al. Feb 2003 A1
20030040478 Drucker et al. Feb 2003 A1
20030045825 Etheredge, III Mar 2003 A1
20030064190 Carte Apr 2003 A1
20030069529 Augustine et al. Apr 2003 A1
20030069535 Shalaby Apr 2003 A1
20030069536 Greter et al. Apr 2003 A1
20030069563 Johnson Apr 2003 A1
20030088202 Gilman May 2003 A1
20030095879 Oh et al. May 2003 A1
20030099558 Chang May 2003 A1
20030108430 Yoshida et al. Jun 2003 A1
20030110939 Able et al. Jun 2003 A1
20030125646 Whitlock Jul 2003 A1
20030125649 Mcintosh et al. Jul 2003 A1
20030133812 Puff et al. Jul 2003 A1
20030143189 Askill et al. Jul 2003 A1
20030144619 Augustine Jul 2003 A1
20030153860 Nielsen et al. Aug 2003 A1
20030161735 Kim et al. Aug 2003 A1
20030171675 Rosenberg Sep 2003 A1
20030175125 Kwon et al. Sep 2003 A1
20030175135 Heo et al. Sep 2003 A1
20030175798 Raees et al. Sep 2003 A1
20030183653 Bills Oct 2003 A1
20030188754 Heaton et al. Oct 2003 A1
20030212357 Pace Nov 2003 A1
20030212431 Brady et al. Nov 2003 A1
20030219469 Johnson et al. Nov 2003 A1
20030225347 Argenta et al. Dec 2003 A1
20030230191 Ohrle et al. Dec 2003 A1
20040005222 Yoshida et al. Jan 2004 A1
20040006319 Lina et al. Jan 2004 A1
20040019342 Nagasuna et al. Jan 2004 A1
20040024351 Greter et al. Feb 2004 A1
20040033466 Shellard et al. Feb 2004 A1
20040037897 Benjamin et al. Feb 2004 A1
20040039391 Argenta et al. Feb 2004 A1
20040049187 Burnett et al. Mar 2004 A1
20040054338 Bybordi et al. Mar 2004 A1
20040057855 Gerlach et al. Mar 2004 A1
20040064111 Lockwood et al. Apr 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040066097 Kobayashi et al. Apr 2004 A1
20040071568 Hyeon Apr 2004 A1
20040071572 Greter et al. Apr 2004 A1
20040073152 Karason et al. Apr 2004 A1
20040076662 Riesinger Apr 2004 A1
20040087884 Haddock et al. May 2004 A1
20040115076 Lilie et al. Jun 2004 A1
20040118460 Stinson Jun 2004 A1
20040122434 Argenta et al. Jun 2004 A1
20040126250 Tsuchiya et al. Jul 2004 A1
20040126413 Sigurjonsson Jul 2004 A1
20040127862 Bubb et al. Jul 2004 A1
20040127863 Bubb et al. Jul 2004 A1
20040156730 Lilie et al. Aug 2004 A1
20040163713 Schulze et al. Aug 2004 A1
20040167482 Watson Aug 2004 A1
20040167617 Voellmicke et al. Aug 2004 A1
20040171976 Johson Sep 2004 A1
20040171998 Marasco, Jr. Sep 2004 A1
20040182237 Headley et al. Sep 2004 A1
20040189103 Duncan et al. Sep 2004 A1
20040241214 Kirkwood et al. Dec 2004 A1
20040249353 Risk, Jr. et al. Dec 2004 A1
20050012616 Forster et al. Jan 2005 A1
20050013957 Leschinsky Jan 2005 A1
20050020955 Sanders et al. Jan 2005 A1
20050031470 Lee Feb 2005 A1
20050045461 Sweetland et al. Mar 2005 A1
20050065471 Kuntz Mar 2005 A1
20050080372 Nielsen Apr 2005 A1
20050085768 Greter et al. Apr 2005 A1
20050090787 Risk et al. Apr 2005 A1
20050098031 Yoon et al. May 2005 A1
20050110190 Giardini May 2005 A1
20050111987 Yoo et al. May 2005 A1
20050119737 Bene et al. Jun 2005 A1
20050123422 Lilie Jun 2005 A1
20050124966 Karpowicz et al. Jun 2005 A1
20050129540 Puff Jun 2005 A1
20050131327 Lockwood et al. Jun 2005 A1
20050135946 Kang et al. Jun 2005 A1
20050137539 Biggie et al. Jun 2005 A1
20050142007 Lee et al. Jun 2005 A1
20050142008 Jung et al. Jun 2005 A1
20050155657 Kack et al. Jul 2005 A1
20050163635 Berwanger et al. Jul 2005 A1
20050165350 Greter et al. Jul 2005 A1
20050209560 Boukhny et al. Sep 2005 A1
20050228329 Boehringer et al. Oct 2005 A1
20050230422 Muller et al. Oct 2005 A1
20050245850 Freyre et al. Nov 2005 A1
20050251117 Anderson et al. Nov 2005 A1
20050271526 Chang et al. Dec 2005 A1
20050272142 Horita Dec 2005 A1
20050276706 Radue Dec 2005 A1
20050283105 Heaton et al. Dec 2005 A1
20060009744 Edrman et al. Jan 2006 A1
20060017332 Kang et al. Jan 2006 A1
20060018771 Song et al. Jan 2006 A1
20060019144 Hidaka et al. Jan 2006 A1
20060024181 Kim Feb 2006 A1
20060029650 Coffey Feb 2006 A1
20060029675 Ginther Feb 2006 A1
20060039806 Becker Feb 2006 A1
20060056979 Yoo et al. Mar 2006 A1
20060056980 Yoo et al. Mar 2006 A1
20060057000 Hyeon Mar 2006 A1
20060061024 Jung et al. Mar 2006 A1
20060069365 Sperl et al. Mar 2006 A1
20060070458 Jones et al. Apr 2006 A1
20060073036 Debrito et al. Apr 2006 A1
20060079599 Arthur Apr 2006 A1
20060086598 Sneek et al. Apr 2006 A1
20060107642 Smith et al. May 2006 A1
20060110259 Puff et al. May 2006 A1
20060118190 Takehana et al. Jun 2006 A1
20060122558 Sherman et al. Jun 2006 A1
20060149170 Boynton et al. Jul 2006 A1
20060173514 Biel et al. Aug 2006 A1
20060191575 Naesje Aug 2006 A1
20060192259 Silverbrook Aug 2006 A1
20060210411 Hyeon Sep 2006 A1
20060213527 Argenta et al. Sep 2006 A1
20060216165 Lee Sep 2006 A1
20060222532 Lee et al. Oct 2006 A1
20060228224 Hong et al. Oct 2006 A1
20060245947 Seto et al. Nov 2006 A1
20060251523 Lee et al. Nov 2006 A1
20060253082 Mcintosh et al. Nov 2006 A1
20060259102 Slatkine Nov 2006 A1
20060273109 Keller Dec 2006 A1
20060282028 Howard et al. Dec 2006 A1
20060282174 Haines Dec 2006 A1
20060287632 Sarangapani Dec 2006 A1
20070004896 Ito et al. Jan 2007 A1
20070005028 Risk et al. Jan 2007 A1
20070009580 DiCosmo et al. Jan 2007 A1
20070016152 Karpowicz et al. Jan 2007 A1
20070021697 Ginther et al. Jan 2007 A1
20070032741 Hibner et al. Feb 2007 A1
20070032762 Vogel Feb 2007 A1
20070032778 Heaton et al. Feb 2007 A1
20070038172 Zamierowski Feb 2007 A1
20070040454 Freudenberger et al. Feb 2007 A1
20070041856 Hansen et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070078444 Larsson Apr 2007 A1
20070091614 Kaisser et al. Apr 2007 A1
20070128055 Lee Jun 2007 A1
20070141101 Nugent et al. Jun 2007 A1
20070147947 Stenton et al. Jun 2007 A1
20070164047 Reidt et al. Jul 2007 A1
20070179460 Adahan Aug 2007 A1
20070185463 Mulligan Aug 2007 A1
20070196214 Bocchiola Aug 2007 A1
20070203062 Ellis-Behnke et al. Aug 2007 A1
20070219513 Lina et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070255187 Branch Nov 2007 A1
20070256428 Unger et al. Nov 2007 A1
20070260207 Ugander et al. Nov 2007 A1
20070260226 Jaeb et al. Nov 2007 A1
20070265586 Joshi Nov 2007 A1
20070276195 Xu et al. Nov 2007 A1
20070276309 Xu et al. Nov 2007 A1
20070282283 Kaern et al. Dec 2007 A1
20070295201 Dadd Dec 2007 A1
20080004549 Anderson et al. Jan 2008 A1
20080009812 Riesinger Jan 2008 A1
20080015526 Reiner et al. Jan 2008 A1
20080020178 Oehrle et al. Jan 2008 A1
20080021356 Castello Escude et al. Jan 2008 A1
20080031748 Ihle et al. Feb 2008 A1
20080033352 Annis et al. Feb 2008 A1
20080039761 Heaton et al. Feb 2008 A1
20080045887 Larsson et al. Feb 2008 A1
20080051708 Kumar et al. Feb 2008 A1
20080051716 Stutz Feb 2008 A1
20080060550 MacDonald et al. Mar 2008 A1
20080071216 Locke et al. Mar 2008 A1
20080071234 Kelch et al. Mar 2008 A1
20080071235 Locke et al. Mar 2008 A1
20080082040 Kubler et al. Apr 2008 A1
20080089173 Lu et al. Apr 2008 A1
20080094753 Brodkin et al. Apr 2008 A1
20080110336 Bovill et al. May 2008 A1
20080125697 Gao May 2008 A1
20080125698 Gerg et al. May 2008 A1
20080132821 Propp et al. Jun 2008 A1
20080200905 Heaton Aug 2008 A1
20080206155 Tamarkin et al. Aug 2008 A1
20080208147 Argenta et al. Aug 2008 A1
20080208163 Wilkie Aug 2008 A1
20080211435 Imagawa Sep 2008 A1
20080223378 Henderson et al. Sep 2008 A1
20080234641 Locke et al. Sep 2008 A1
20080240942 Heinrich et al. Oct 2008 A1
20080254103 Harris et al. Oct 2008 A1
20080260551 Simmons Oct 2008 A1
20080281281 Meyer et al. Nov 2008 A1
20080287880 Keller Nov 2008 A1
20080294147 Radl et al. Nov 2008 A1
20080300555 Olson et al. Dec 2008 A1
20080306407 Taylor Dec 2008 A1
20080306456 Riesinger Dec 2008 A1
20080310980 Ramsdorf et al. Dec 2008 A1
20080312572 Riesinger Dec 2008 A1
20080312613 Heaton et al. Dec 2008 A1
20080314929 Keller Dec 2008 A1
20090005746 Nielsen et al. Jan 2009 A1
20090012484 Nielsen et al. Jan 2009 A1
20090020561 Keller Jan 2009 A1
20090022779 Kelly et al. Jan 2009 A1
20090028733 Duwel Jan 2009 A1
20090030086 Eady et al. Jan 2009 A1
20090036873 Nielsen et al. Feb 2009 A1
20090048556 Durand Feb 2009 A1
20090053081 Griffiths Feb 2009 A1
20090054855 Blott et al. Feb 2009 A1
20090071551 Chalich Mar 2009 A1
20090081049 Tian et al. Mar 2009 A1
20090082740 Lockwood et al. Mar 2009 A1
20090087323 Blakey et al. Apr 2009 A1
20090093550 Rolfes et al. Apr 2009 A1
20090093779 Riesinger Apr 2009 A1
20090098073 MacDonald et al. Apr 2009 A1
20090114293 Kanai et al. May 2009 A1
20090125004 Shen et al. May 2009 A1
20090129986 Wimberger-Friedl et al. May 2009 A1
20090131892 Karpowicz et al. May 2009 A1
20090134186 Keller May 2009 A1
20090137973 Karpowicz et al. May 2009 A1
20090149821 Scherson et al. Jun 2009 A1
20090157017 Ambrosio Jun 2009 A1
20090157024 Song Jun 2009 A1
20090166411 Kramer et al. Jul 2009 A1
20090192467 Hansen et al. Jul 2009 A1
20090196844 Choi et al. Aug 2009 A1
20090198201 Adahan Aug 2009 A1
20090204085 Biggie et al. Aug 2009 A1
20090206778 Roh et al. Aug 2009 A1
20090216170 Robinson et al. Aug 2009 A1
20090216204 Bhavaraju et al. Aug 2009 A1
20090221977 Blott et al. Sep 2009 A1
20090227969 Jaeb Sep 2009 A1
20090234306 Vitaris Sep 2009 A1
20090254053 Svensby et al. Oct 2009 A1
20090254066 Heaton Oct 2009 A1
20090259203 Hu et al. Oct 2009 A1
20090264807 Haggstrom et al. Oct 2009 A1
20090270820 Johnson Oct 2009 A1
20090275872 Addison et al. Nov 2009 A1
20090275922 Coulthard et al. Nov 2009 A1
20090287129 Boehringer et al. Nov 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299251 Buan Dec 2009 A1
20090299255 Kazala, Jr. et al. Dec 2009 A1
20090299306 Buan Dec 2009 A1
20090304534 Richter Dec 2009 A1
20090312723 Blott et al. Dec 2009 A1
20100004611 Aali Jan 2010 A1
20100016767 Jones et al. Jan 2010 A1
20100022972 Lina et al. Jan 2010 A1
20100022990 Karpowicz et al. Jan 2010 A1
20100030170 Keller et al. Feb 2010 A1
20100030171 Canada et al. Feb 2010 A1
20100030178 MacMeccan et al. Feb 2010 A1
20100036305 Green Feb 2010 A1
20100036334 Heagle et al. Feb 2010 A1
20100042059 Pratt et al. Feb 2010 A1
20100068820 Meathrel et al. Mar 2010 A1
20100069829 Hutchinson et al. Mar 2010 A1
20100069850 Fabo Mar 2010 A1
20100069858 Olson Mar 2010 A1
20100069863 Olson Mar 2010 A1
20100094234 Ramella et al. Apr 2010 A1
20100098566 Kang Apr 2010 A1
20100100160 Edman et al. Apr 2010 A1
20100106112 Vogel Apr 2010 A1
20100106117 Lockwood et al. Apr 2010 A1
20100121286 Locke et al. May 2010 A1
20100122417 Vrzalik et al. May 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100145289 Line et al. Jun 2010 A1
20100150991 Bernstein Jun 2010 A1
20100159192 Cotton Jun 2010 A1
20100160878 Hunt et al. Jun 2010 A1
20100168633 Bougherara Jul 2010 A1
20100191178 Ross et al. Jul 2010 A1
20100191196 Heagle Jul 2010 A1
20100191198 Heagle Jul 2010 A1
20100204663 Wudyka Aug 2010 A1
20100210986 Sanders Aug 2010 A1
20100211030 Turner et al. Aug 2010 A1
20100228205 Hu et al. Sep 2010 A1
20100230467 Crisuolo et al. Sep 2010 A1
20100244780 Turner Sep 2010 A1
20100249733 Blott et al. Sep 2010 A9
20100262090 Riesinger Oct 2010 A1
20100262091 Larsson Oct 2010 A1
20100265649 Singh et al. Oct 2010 A1
20100268176 Johnson et al. Oct 2010 A1
20100268179 Kelch et al. Oct 2010 A1
20100280435 Raney et al. Nov 2010 A1
20100280468 Haggstrom et al. Nov 2010 A1
20100280469 Hall Nov 2010 A1
20100286639 Scholz Nov 2010 A1
20100292632 Mulvihill et al. Nov 2010 A1
20100305490 Coulthard et al. Dec 2010 A1
20100305526 Robinson et al. Dec 2010 A1
20100318043 Malhi et al. Dec 2010 A1
20100318052 Ha et al. Dec 2010 A1
20100318071 Wudyka Dec 2010 A1
20110000069 Ramsdorf et al. Jan 2011 A1
20110004172 Eckstein et al. Jan 2011 A1
20110004173 Hu et al. Jan 2011 A1
20110015587 Tumey et al. Jan 2011 A1
20110015593 Svedman et al. Jan 2011 A1
20110020588 Kinugawa et al. Jan 2011 A1
20110021431 Jones et al. Jan 2011 A1
20110022013 Boynton et al. Jan 2011 A1
20110028290 Ozawa Feb 2011 A1
20110028919 Johnnison et al. Feb 2011 A1
20110028920 Johannison Feb 2011 A1
20110028921 Hartwell et al. Feb 2011 A1
20110033503 Sinko et al. Feb 2011 A1
20110034869 Greter et al. Feb 2011 A1
20110034888 Aali Feb 2011 A1
20110034892 Buan Feb 2011 A1
20110034894 Riesinger Feb 2011 A1
20110038741 Lissner et al. Feb 2011 A1
20110054422 Locke et al. Mar 2011 A1
20110054423 Blott et al. Mar 2011 A1
20110071415 Karwoski et al. Mar 2011 A1
20110081267 McCrone et al. Apr 2011 A1
20110086077 McCrea et al. Apr 2011 A1
20110092927 Wilkes et al. Apr 2011 A1
20110092958 Jacobs Apr 2011 A1
20110098600 Matsumura et al. Apr 2011 A1
20110103984 Santa May 2011 A1
20110105963 Hu et al. May 2011 A1
20110106030 Scholz May 2011 A1
20110112492 Bharti et al. May 2011 A1
20110118683 Weston May 2011 A1
20110125066 Robinson et al. May 2011 A1
20110130712 Topaz Jun 2011 A1
20110171044 Flanigan Jul 2011 A1
20110172617 Riesinger Jul 2011 A1
20110176945 Drevet Jul 2011 A1
20110176946 Drevet Jul 2011 A1
20110224631 Simmons Sep 2011 A1
20110229352 Herbert Sep 2011 A1
20110236265 Hasui et al. Sep 2011 A1
20110236277 Lee et al. Sep 2011 A1
20110251569 Turner et al. Oct 2011 A1
20110257572 Locke et al. Oct 2011 A1
20110270201 Bubb et al. Nov 2011 A1
20110270202 Boehringer et al. Nov 2011 A1
20110295220 Heaton et al. Dec 2011 A1
20110311379 Hale et al. Dec 2011 A1
20110313373 Riesinger Dec 2011 A1
20110313374 Lockwood et al. Dec 2011 A1
20120000208 Hon et al. Jan 2012 A1
20120008817 Grinker et al. Jan 2012 A1
20120046625 Johannison Feb 2012 A1
20120095380 Gergley et al. Apr 2012 A1
20120109085 McNeil May 2012 A1
20120130332 Cotton et al. May 2012 A1
20120184930 Johannison Jul 2012 A1
20120220960 Ruland Aug 2012 A1
20120251359 Neelakantan et al. Oct 2012 A1
20120259299 Ryu et al. Oct 2012 A1
20120271256 Locke et al. Oct 2012 A1
20120289895 Tsoukalis Nov 2012 A1
20120289913 Eckstein et al. Nov 2012 A1
20120289914 Eckstein et al. Nov 2012 A1
20120301341 Ota et al. Nov 2012 A1
20130017110 Villagomez et al. Jan 2013 A1
20130042753 Becker et al. Feb 2013 A1
20130085462 Nip et al. Apr 2013 A1
20130090613 Kelch et al. Apr 2013 A1
20130090615 Jaeb et al. Apr 2013 A1
20130102979 Coulthard et al. Apr 2013 A1
20130118622 Patzold et al. May 2013 A1
20130123755 Locke et al. May 2013 A1
20130138054 Fleischmann May 2013 A1
20130144230 Wu et al. Jun 2013 A1
20130150814 Buan Jun 2013 A1
20130165878 Heagle Jun 2013 A1
20130209277 Locke et al. Aug 2013 A1
20130209279 Locke et al. Aug 2013 A1
20130209281 Locke et al. Aug 2013 A1
20130213506 Chen et al. Aug 2013 A1
20130223979 Locke et al. Aug 2013 A1
20130267917 Pan et al. Oct 2013 A1
20130274688 Weston Oct 2013 A1
20130280113 Miranda et al. Oct 2013 A1
20130296762 Toth Nov 2013 A1
20130331822 Patel et al. Dec 2013 A1
20130338614 Heaton et al. Dec 2013 A1
20130340870 Ito et al. Dec 2013 A1
20140072149 Yan et al. Mar 2014 A1
20140100516 Hunt et al. Apr 2014 A1
20140114236 Gordon Apr 2014 A1
20140114237 Gordon Apr 2014 A1
20140114268 Auguste et al. Apr 2014 A1
20140155849 Heaton et al. Jun 2014 A1
20140163490 Locke et al. Jun 2014 A1
20140194835 Ehlert Jul 2014 A1
20140228791 Hartwell Aug 2014 A1
20140236106 Locke et al. Aug 2014 A1
20140236109 Greener Aug 2014 A1
20140276487 Locke et al. Sep 2014 A1
20140303551 Germain et al. Oct 2014 A1
20140316359 Collinson et al. Oct 2014 A1
20140323906 Peatfield et al. Oct 2014 A1
20140343519 Weston Nov 2014 A1
20150025482 Begin et al. Jan 2015 A1
20150032035 Banwell et al. Jan 2015 A1
20150051560 Askem Feb 2015 A1
20150065965 Haggstrom et al. Mar 2015 A1
20150073363 Kelch et al. Mar 2015 A1
20150094673 Pratt et al. Apr 2015 A1
20150094674 Pratt et al. Apr 2015 A1
20150209492 Blott et al. Jul 2015 A1
20150258256 Jaeb et al. Sep 2015 A1
20150250931 Bharti et al. Oct 2015 A1
20160081859 Hartwell Mar 2016 A1
20160317357 Vitaris et al. Nov 2016 A1
20170128642 Buan May 2017 A1
20170181896 Hartwell Jun 2017 A1
20170266051 Hartwell Sep 2017 A1
20180133065 Hartwell May 2018 A1
20180214317 Hartwell Aug 2018 A1
20180235816 Hartwell Aug 2018 A1
20180243142 Hartwell Aug 2018 A1
20180311078 Hartwell Nov 2018 A1
20190142647 Hartwell May 2019 A1
20190224387 Weston Jul 2019 A1
20200061254 Joshi et al. Feb 2020 A1
Foreign Referenced Citations (313)
Number Date Country
2186074 Dec 1994 CN
201664463 Dec 2010 CN
847475 Aug 1952 DE
3 137 839 Mar 1983 DE
3 032 092 Oct 1984 DE
34 43 101 May 1986 DE
3 935 818 May 1991 DE
4 012 232 Oct 1991 DE
198 44 355 Apr 2000 DE
20 2004 017 052 Jul 2005 DE
0 020 662 Jul 1984 EP
0 208 395 Jan 1987 EP
0 340 018 Nov 1989 EP
0 355 186 Feb 1990 EP
0353972 Feb 1990 EP
0 512 543 Nov 1992 EP
0 521 434 Jan 1993 EP
0 619 105 Oct 1994 EP
0 759 521 Feb 1997 EP
0 775 825 May 1997 EP
0 793 019 Sep 1997 EP
0 809 028 Nov 1997 EP
0 858 810 Aug 1998 EP
0 777 504 Oct 1998 EP
0 888 141 Jan 1999 EP
0 898 076 Feb 1999 EP
1 007 015 Jun 2000 EP
1 013 290 Jun 2000 EP
1 029 585 Aug 2000 EP
1 105 171 Jun 2001 EP
1 105 180 Jun 2001 EP
1 107 813 Jun 2001 EP
1 411 874 Jul 2001 EP
1 030 657 Oct 2001 EP
1 306 123 May 2003 EP
1 440 737 Jul 2004 EP
1 449 971 Aug 2004 EP
1 476 217 Nov 2004 EP
1 726 276 Nov 2006 EP
1 923 077 Nov 2006 EP
1 880 840 Jan 2008 EP
1 955 887 Aug 2008 EP
1 985 270 Oct 2008 EP
1 121 163 Nov 2008 EP
2 185 206 Jan 2009 EP
2 178 573 Feb 2009 EP
2 098 257 Sep 2009 EP
2 111 804 Oct 2009 EP
1 985 270 Dec 2009 EP
2 161 448 Mar 2010 EP
2 326 295 Mar 2010 EP
2 216 573 Aug 2010 EP
2 218 431 Aug 2010 EP
2 302 127 Mar 2011 EP
2 335 749 Jun 2011 EP
2 349 155 Aug 2011 EP
1 263 366 Sep 2011 EP
2 420 214 Feb 2012 EP
2 021 046 Mar 2012 EP
2 462 908 Jun 2012 EP
2 603 699 Jun 2013 EP
2 305 325 Apr 2014 EP
2 345 437 Apr 2014 EP
2 687 245 Sep 2014 EP
2 544 642 Jan 2015 EP
2 648 668 Jan 2015 EP
3 072 542 Sep 2016 EP
3 062 751 Aug 2017 EP
3 257 486 Dec 2017 EP
1 163 907 Oct 1958 FR
2 939 320 Jun 2010 FR
114754 Apr 1918 GB
236350 Jul 1925 GB
641061 Aug 1950 GB
1224009 Mar 1971 GB
1255395 Dec 1971 GB
1400124 Jul 1975 GB
1549756 Aug 1979 GB
2061732 May 1981 GB
2195255 Apr 1988 GB
2273133 Jun 1994 GB
2288734 Nov 1995 GB
2306580 May 1997 GB
2307180 May 1997 GB
2378392 Feb 2003 GB
2415908 Jan 2006 GB
2424582 Oct 2006 GB
2435419 Feb 2007 GB
2433298 Mar 2007 GB
2511523 Sep 2014 GB
0722820 Jul 2019 GB
59-86824 Jun 1984 JP
59-87824 Jun 1984 JP
S5986824 Jun 1984 JP
S5987824 Jun 1984 JP
S6180018 Apr 1986 JP
S61-80018 May 1986 JP
H04-354722 Dec 1992 JP
2001-314479 Nov 2001 JP
2003-165843 Jun 2003 JP
2004-000465 Jan 2004 JP
2005-334188 Dec 2005 JP
131622 Aug 2013 RU
1251912 Apr 1983 SU
WO 198300742 Mar 1983 WO
WO 198401904 May 1984 WO
WO 199011795 Oct 1990 WO
WO 199100718 Jan 1991 WO
WO 1992009301 Jun 1992 WO
WO 199209651 Jun 1992 WO
WO 199220299 Nov 1992 WO
WO 199306802 Apr 1993 WO
WO 199309176 May 1993 WO
WO 1994020133 Sep 1994 WO
WO 199421312 Sep 1994 WO
WO 199605873 Feb 1996 WO
WO 199640174 Dec 1996 WO
WO 199703717 Feb 1997 WO
WO 199733922 Sep 1997 WO
WO 199742986 Nov 1997 WO
WO 199803267 Jan 1998 WO
WO 199806444 Feb 1998 WO
WO 1999001173 Jan 1999 WO
WO 199917698 Apr 1999 WO
WO 199930629 Jun 1999 WO
WO 1999047097 Sep 1999 WO
WO 199965536 Dec 1999 WO
WO 2000000743 Jan 2000 WO
WO 200007653 Feb 2000 WO
WO 200038752 Jul 2000 WO
WO 200049968 Aug 2000 WO
WO 200050143 Aug 2000 WO
WO 200056378 Sep 2000 WO
WO 200059424 Oct 2000 WO
WO 200061206 Oct 2000 WO
WO 200062827 Oct 2000 WO
WO 2000064396 Nov 2000 WO
WO 2000079154 Dec 2000 WO
WO 200119430 Mar 2001 WO
WO 200134223 May 2001 WO
WO 200137922 May 2001 WO
WO 200137922 May 2001 WO
WO 2001062312 Aug 2001 WO
WO 2001066017 Sep 2001 WO
WO 200185248 Nov 2001 WO
WO 200189431 Nov 2001 WO
WO 200202079 Jan 2002 WO
WO 2002070040 Sep 2002 WO
WO 2002083046 Oct 2002 WO
WO 2002092783 Nov 2002 WO
WO 2002094256 Nov 2002 WO
WO 2002102864 Dec 2002 WO
WO 2003074100 Sep 2003 WO
WO 2003085810 Oct 2003 WO
WO 2003092620 Nov 2003 WO
WO 2004007960 Jan 2004 WO
WO 2004024300 Mar 2004 WO
WO 2004037334 May 2004 WO
WO 2004041064 May 2004 WO
WO 2004054632 Jul 2004 WO
WO 2004077387 Sep 2004 WO
WO 2004081421 Sep 2004 WO
WO 2005009488 Feb 2005 WO
WO 2005016179 Feb 2005 WO
WO 2005017000 Feb 2005 WO
WO 2005018695 Mar 2005 WO
WO 2005025447 Mar 2005 WO
WO 2005025666 Mar 2005 WO
WO 2005046761 May 2005 WO
WO 2005046762 May 2005 WO
WO 2005051461 Jun 2005 WO
WO 2005070480 Aug 2005 WO
WO 2005079718 Sep 2005 WO
WO 2005082435 Sep 2005 WO
WO 2005105175 Nov 2005 WO
WO 2005105180 Nov 2005 WO
WO 2005115497 Dec 2005 WO
WO 2005118011 Dec 2005 WO
WO 2005123170 Dec 2005 WO
WO 2006014534 Feb 2006 WO
WO 2006030054 Mar 2006 WO
WO 2006034128 Mar 2006 WO
WO 2006048246 May 2006 WO
WO 2006052745 May 2006 WO
WO 2006052839 May 2006 WO
WO-2006052338 May 2006 WO
WO 2006056294 Jun 2006 WO
WO 2006058801 Jun 2006 WO
WO 2006062276 Jun 2006 WO
WO 2006081403 Aug 2006 WO
WO 2006092333 Sep 2006 WO
WO 2006116992 Nov 2006 WO
WO 2006117207 Nov 2006 WO
WO 2006135506 Dec 2006 WO
WO 2007002835 Jan 2007 WO
WO 2007013064 Feb 2007 WO
WO 2007019038 Feb 2007 WO
WO 2007024230 Mar 2007 WO
WO 2007030598 Mar 2007 WO
WO 2007030599 Mar 2007 WO
WO 2007030601 Mar 2007 WO
WO 2007031757 Mar 2007 WO
WO 2007051599 May 2007 WO
WO 2007084792 Jul 2007 WO
WO 2007085396 Aug 2007 WO
WO 2007106592 Sep 2007 WO
WO 2007106594 Sep 2007 WO
WO 2007124198 Nov 2007 WO
WO 2007133618 Nov 2007 WO
WO 2008013896 Jan 2008 WO
WO 2008027449 Mar 2008 WO
WO 2008031418 Mar 2008 WO
WO 2008036345 Mar 2008 WO
WO 2008039223 Apr 2008 WO
WO 2008040020 Apr 2008 WO
WO 2008041926 Apr 2008 WO
WO 2008062176 May 2008 WO
WO 2008076407 Jun 2008 WO
WO 2008082444 Jul 2008 WO
WO 2008100437 Aug 2008 WO
WO 2008100440 Aug 2008 WO
WO 2008112304 Sep 2008 WO
WO 2008134544 Nov 2008 WO
WO 2008134774 Nov 2008 WO
WO 2008141228 Nov 2008 WO
WO 2008141470 Nov 2008 WO
WO 2009019227 Feb 2009 WO
WO 2009019229 Feb 2009 WO
WO 2009034322 Mar 2009 WO
WO 2009042514 Apr 2009 WO
WO 2009047524 Apr 2009 WO
WO 2009052193 Apr 2009 WO
WO 2009060327 May 2009 WO
WO 2009062327 May 2009 WO
WO 2009066105 May 2009 WO
WO 2009066106 May 2009 WO
WO 2009070905 Jun 2009 WO
WO 2009078790 Jun 2009 WO
WO 2009089390 Jul 2009 WO
WO 2009095170 Aug 2009 WO
WO 2009098696 Aug 2009 WO
WO 2009103031 Aug 2009 WO
WO 2009111657 Sep 2009 WO
WO 2009117635 Sep 2009 WO
WO 2009120951 Oct 2009 WO
WO 2009122989 Oct 2009 WO
WO 2009124100 Oct 2009 WO
WO 2009126833 Oct 2009 WO
WO 2009145703 Dec 2009 WO
WO 2009146441 Dec 2009 WO
WO 2009151380 Dec 2009 WO
WO 2009156709 Dec 2009 WO
WO 2009158124 Dec 2009 WO
WO 2009158128 Dec 2009 WO
WO 2009158130 Dec 2009 WO
WO 2010026251 Mar 2010 WO
WO 2010033271 Mar 2010 WO
WO 2010051068 May 2010 WO
WO 2010051418 May 2010 WO
WO 2010059712 May 2010 WO
WO 2010072309 Jul 2010 WO
WO 2010072349 Jul 2010 WO
WO 2010072395 Jul 2010 WO
WO 2010075313 Jul 2010 WO
WO 2010083135 Jul 2010 WO
WO 2010118316 Oct 2010 WO
WO 2010120776 Oct 2010 WO
WO 2010141271 Dec 2010 WO
WO 2010142959 Dec 2010 WO
WO 2010147592 Dec 2010 WO
WO 2011019476 Feb 2011 WO
WO 2011023275 Mar 2011 WO
WO 2011082461 Jul 2011 WO
WO 2011135285 Nov 2011 WO
WO 2011135286 Nov 2011 WO
WO 2011135287 Nov 2011 WO
WO 2011144888 Nov 2011 WO
WO 2011148188 Dec 2011 WO
WO 2012022484 Feb 2012 WO
WO 2012028842 Mar 2012 WO
WO 2012048179 Apr 2012 WO
WO 2012078707 Jun 2012 WO
WO 2012088572 Jul 2012 WO
WO 2012131237 Oct 2012 WO
WO 2012140180 Oct 2012 WO
WO 2012140378 Oct 2012 WO
WO 2012143665 Oct 2012 WO
WO 2013006932 Jan 2013 WO
WO 2013010907 Jan 2013 WO
WO 2013019017 Feb 2013 WO
WO 2013064852 May 2013 WO
WO 2013065423 May 2013 WO
WO 2013083800 Jun 2013 WO
WO 2013090810 Jun 2013 WO
WO 2013117945 Aug 2013 WO
WO 2013118447 Aug 2013 WO
WO 2013119854 Aug 2013 WO
WO 2013133652 Sep 2013 WO
WO 2013136181 Sep 2013 WO
WO 2013149078 Oct 2013 WO
WO 2014008348 Jan 2014 WO
WO 2014016759 Jan 2014 WO
WO 2014020440 Feb 2014 WO
WO 2014020443 Feb 2014 WO
WO 2014108476 Jul 2014 WO
WO 2014113253 Jul 2014 WO
WO 2014113504 Jul 2014 WO
WO 2014107285 Sep 2014 WO
WO 2014143488 Sep 2014 WO
WO 2015022334 Feb 2015 WO
WO 2015022340 Feb 2015 WO
WO 2015023515 Feb 2015 WO
WO 2015031216 Mar 2015 WO
Non-Patent Literature Citations (116)
Entry
US 6,216,701 B1, 04/2001, Heaton et al. (withdrawn)
US 6,306,115 B1, 10/2001, Kelly et al. (withdrawn)
U.S. Appl. No. 61/828,604, filed May 29, 2013, Collinson et al.
U.S. Appl. No. 61/829,187, filed May 30, 2013, Collinson et al.
U.S. Appl. No. 61/906,865, filed Nov. 20, 2013, Collinson et al.
U.S. Appl. No. 61/907,350, filed Nov. 21, 2013, Collinson et al.
Achterberg, V., Ph.D., Hydroactive dressings and serum proteins: an in vitro study, Journal of Wound Care, February, vol. 5, No. 2, 1996 (pp. 79-82).
Argenta, Louis C., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment; Clinical Experience”, Ann Plas Surg 1997;38:563-577 (Dec. 10, 1996).
Aubrey, D.A., et al., “Treatment of the Perineal Wound after Proctectomy by Intermittent Irrigation”, Arch. Surg., Oct. 1984, 119, 1141-1144.
Bagautdinov, N.A., “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” in current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye. Volkov et al. (Chuvash State University, Cheboksary, USSR 1986) pp. 94-96 (with English translation).
Braglina, I.O., et al. “Russian Chemical Bulletin”, Dec. 31, 1983.
Chariker, M.E., et al., “Effective Management of Incisional and Cutaneous Fistulae with Closed Suction Wound Drainage,” Contemporary Surgery. Jun. 1989, pp. 59-63, vol. 34.
Chintamani, et al., “Half versus full vacuum suction drainage after modified radical mastectomy for breast cancer—a prospective randomized clinical trial”, Research Article (Jan. 27, 2005), 1-5.
Davydov, Y.A., et al., The Bacteriological & Cytological Assessment of Vacuum Therapy of Purulent Wounds, Vestnik Chirurgia 1988, October Edition 48-52 (in Russian with English translation). 1987.
Davydov, Yu A., et al., “Concepts for Clinical Biological Management of the Wound Process in the Treatment of Purulent Wounds Using Vacuum Therapy”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 15-17.
Davydov, Yu A., et al., “The Bacteriological and Cytological Assessment of Vacuum Therapy of Purulent Wounds”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 11-14.
Davydov, Yu A., et al., “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 5-7.
De Lange, M.Y. , et al., “Vacuum-Assisted Closure: Indications and Clinical Experience”, Eur J Plast Surg (2000) 2;178-182 (Feb. 9, 2000).
Dilmaghani et al., “A Method for Closed Irrigation and Suction Therapy in Deep Wound Infections,” Journal of Bone and Joint Surgery, 1969, vol. 51-A, No. 2, pp. 323-342.
Hartz, R.S. et al., Healing of the Perineal Wound, Arch. Surg., Apr. 1980, 115, 471-474.
Health Technology, Literature R., “Vacuum Assisted Closure Therapy for Wound Care”, Health Technology Literature Review (Dec. 2004), 3-59.
Kalypto Medical, NPD 1000 Negative Pressure Wound Care System, Clinician & Patient Instructions for Use (publication date unknown, believed to be Feb. 2010).
Kalypto Medical, NPD 1000 Product Brochure (publication date unknown, believed to be Nov. 2010).
Kendall ULTEC Hydrocolloid Dressing (4″×4″), product ordering page, web page downloaded Jul. 13, 2014.
Khirugii, Vestnik, “A Collection of Published Studies Complementing the Research and Innovation of Wound Care”, The Kremlin Papers, Perspectives in Wound Care, Russian Medical Journal, Vestnik Khirurgii, Blue Sky Publishing (2004), 2-17.
Kostiuchenok, B. M., et al., “The Vacuum Effect in the Surgical Treatment of Purulent Wounds”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 3-4.
Membrane Filters, in 16 pages, from website: http://www.advantecmfs.com/catalog/filt/membrane.pdf#page=11 (date unknown, but believed to be copyright 2001-2011).
Morykwas, Michael J., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation”, Ann Plast Surg 1997;38:553-562 (Dec. 10, 1996).
Nursing75, Wound Suction: Better Drainage with Fewer Problems, Nursing, vol. 5, No. 10, Oct. 1975, pp. 52-55.
Prevena™ Incision Management System, Clinician Guide, pp. 1-9, Jan. 2010.
Prevena™ Incision Management System, Patient Guide, pp. 1-2, Jan. 2010.
Protz, Kerstin: “Modern Wundauflagen unterstutzen Heilungsprozess”, Wundversorgung: Indikation und Anwendung, Geriatrie Journal, Apr. 2005, pp. 3333-3339, with translation.
Solovev, V. A., et al., “The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract—Guidelines” USSR Ministry of Health, S. M. Kirov Gorky State Medical Institute, 1987 (with English translation).
Solovev, V.A. “Treatment and Prevention of Suture Failures after Gastric Resection” (Dissertation Abstract) (S.M. Kirov Gorky State Medical Institute, Gorky USSR 1988).
Stewart, Joanne, Ph.D., World Wide Wounds—Next generation of products for wound management—2002 (13 pages).
Svedman, P., “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers,” Scand J. Plast. Reconst. Surg., 19:211-213, 1985.
Svedman, P., “Irrigation Treatment of Leg Ulcers,” The Lancet, Sep. 1983, 532-534.
Svedman, P., “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Med. Science: Biomed. Tech.; Clinic. Med.; Surg. and Transplantation, 1979, 7, p. 221.
Svedman, P., et al., “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation,” Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133.
Swift, et al., “Quorum Sensing in Aeromonas hydrophila and Aeromonas salmonicida: Identification of LuxRI Homologs AhyRI and AsaRI and Their Cognate N-Acylhomoserine Lactone Signal Molecules,” J. Bacteriol., 179(17):5271-5281 (1997).
Teder et al., “Continuous Wound Irrigation in the Pig,” Journal of Investigative Surgery, 1990, vol. 3, pp. 399-407.
Tribble, David E. M.D., An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery New York, pp. 511-513, 1972 Vol. 105.
Usupov, Y. N., et al., “Active Wound Drainage”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 8-10.
Venturi, Mark L., “Mechanisms and Clinical Applications of the Vacuum-Assisted Closure (VAC) Device”, Am J Clin Dermatol (2005) 693, 185-194; Review Article (2005), 185-194.
Vijanto, J. and J. Raekallio, Local Hyperalimentation of Open Wounds, Br. J. surg., 1976, 63, 427-430.
Webb, New Techniques in Wound Management: Vacuum-Assisted Wound Closure, Journal of the American Academy of Orthopadic Surgeons, v. 10, No. 5, pp. 303-311, Sep. 2002.
Westaby, S., et al., “A Wound Irrigation Device”, The Lancet, Sep. 2, 1978, pp. 503-504.
Wooding-Scott, Margaret, et al., “No Wound is Too Big for Resourceful Nurses,” RN Dec. 1988, pp. 22-25 USA.
Wound Suction, Nursing, Oct. 1975, USA pp. 52-53.
“Technology Watch”, May 1989, in 1 page.
Hersle, K et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies”, The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, in 4 pages.
International Search Report, re PCT Application No. PCT/GB2008/051090, dated Mar. 4, 2009.
International Preliminary Reporton Patentability, re PCT Application No. PCT/GB2008/051090, dated May 25, 2010.
Bevan, Damon, et al.: “Diverse and potent activities of HGF/SF in skin wound repair”, Journal of Pathology, 2004; 203: 831-838.
English Translation of Invalidity Suit by KCI Medizinprodukte GmbH versus Kalypto Medical, Inc., concerning declaration of invalidity of the German part of the European Patent No. 2 021 046 (German application No. 60 2007 021 330.4) dated Mar. 11, 2015 in 38 pages. EP 2 021 046 is related to the present application by virtue of a common priority claim to U.S. Appl. No. 11/610,458, now U.S. Pat. No. 7,615,036, and U.S. Appl. No. 11/610,458, now U.S. Pat. No. 7,779,625.
Greer, et al., Techniques for Applying Subatmospheric Pressure Dressing to Wounds in Difficult Regions of Anatomy, JWOCN, vol. 26, No. 5, 1999 pp. 250-253.
Info V.A.C. User Manual—KCI—Dec. 2006, in 76 pages.
Landis, E.M. and J.H. Gibbon, Jr., The Effects of Alternate Suction and Pressure on Blood Flow to the Lower Extremities, Alternate Suction and Pressure, J Clin Invest. Sep. 1933, 12(5): 925-961.
Mitchell, Richard N., et al.: “Role of Stem Cells in Tissue Homeostasis”, Pocket Companion to Robbins and Cotran Pathologic Basis of Diseas, 7th Edition., 2006.
Morykwas, M. J., et al.: “Nonsurgical Modalities to Enhance Healing and Care of Soft Tissue Wounds”, Journal of the Southern Orthopaedic Association, vol. 6, No. 4 Winter 1997 in 12 pages.
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System”, spiral booklet, Mar. 2011, in 7 pages.
Preliminary Summary of Facts and Submission, re the Opposition of European Patent No. EP 3 000 448, dated Apr. 20, 2020, in 8 pages.
Consolidated List of Cited Opposition Documents, re European Patent No. EP 3 000 448, dated Jul. 22, 2019, in 1 page.
Japanese Office Action, re JP Application No. 2018-076049, dated Mar. 2, 2020.
Notice of Opposition—Statement of Facts and Evidence, re European Patent No. EP 2 214 611, dated Sep. 26, 2019, in 24 pages.
Notice of Opposition—Statement of Facts and Evidence, re European Patent No. EP 3 000 448, dated Jul. 16, 2019, in 12 pages.
Reply of the Patent Proprietor to the Notice of Opposition, re European Patent No. EP 2 214 611, dated Feb. 21, 2020, in 55 pages.
Reply of the Patent Proprietor to the Notice(s) of Opposition, re the Opposition of European Patent No. 3 000 448, dated Dec. 6, 2019, in 12 pages.
Annex to the Communication, re the Opposition of European Patent No. EP2214610, dated Mar. 3, 2020, 17 pages.
Davydov Y.A., et al., “Concepts of Clinico-Biological Management of Wound Process in Treatment of Purulent Wounds with the Help of Vacuum Therapy,” Vestnik Chirurgia 1991, February Edition, pp. 132-135.
Notice of Opposition—Statement of Facts and Evidence of the European Patent No. 2214610, dated Jul. 8, 2019, 18 pages.
Notice of Response in Summons to Attend Oral Proceedings pursuant to rule 115(1) EPC for European Patent No. 2214611, mailed on Jun. 23, 2020, 19 pages.
Notice of Response in Summons to Attend Oral Proceedings pursuant to rule 115(1) EPC for European Patent No. 3000448, mailed on Jun. 23, 2020, 6 pages.
Reply of the Patent Proprietor to the Notice of Opposition, re the Opposition of European Patent No. 2214610, dated Dec. 3, 2019, 25 pages.
Written Submissions in Preparation to Oral Proceedings, the Opposition of European Patent No. 3000448, dated Sep. 24, 2020, 10 pages.
Kennedy J.F., et al., “Advanced Textiles for Wound Care” (Second Edition), Chapter 10, 2019, 23 pages.
BASF, Elastollan Physical Properties, 2020, 1 page.
U.S. Appl. No. 15/940,788, Wound Dressing, 2018/0214317, Mar. 29, 2018.
U.S. Appl. No. 15/962,932, Wound Dressing, 2018/0235816, Apr. 25, 2018.
U.S. Appl. No. 15/965,734, Wound Dressing, 2018/0243142, Apr. 27,2018.
U.S. Appl. No. 16/028,258, Wound Dressing, 2018/0311078, Jul. 5, 2018.
Communication of a Notice of Opposition and Opponent's Statement of Facts and Arguments for European Patent No. 3254650, dated Sep. 30, 2020, 23 pages.
Declaration of Chris Locke submitted in the Opposition against European Patent No. EP2563308, dated Sep. 7, 2016, 6 pages.
KCI, “V.A.C. Freedom User's Guide,” May 2002, 16 pages.
Opponent's Written Submission in Preparation for the Oral Proceedings, for the Opposition of European Patent No. 2214610, dated Sep. 25, 2020, 5 pages.
Proprietor's Written Submission in Preparation for the Oral Proceedings, for the Opposition of European Patent No. 2214610, dated Oct. 1, 2020, 20 pages.
Brief Communication—Letter from the Opponent, re the Opposition of European Patent No. EP2214611, dated Dec. 16, 2020, 5 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition of European Patent No. EP2214611, dated Dec. 17, 2020, 54 pages.
Summons to Attend Oral Proceedings pursuant to rule 115(1) EPC and Preliminary Summary and Preliminary Opinion, re the Opposition of European Patent No. 3000448, mailed on Oct. 22, 2020, 9 pages.
Brief Communication on Oral proceedings—Letter from the Opponent, re the Opposition of European Patent No. EP2214610, dated Feb. 26, 2021, 6 pages.
Information about the result of oral proceedings for European Patent No. 2214611 mailed on Feb. 12, 2021, 23 pages.
Summons to attend oral proceedings pursuant to Rule 115(1) EPC for Patent No. EP2214610, mailed on Feb. 19, 2021, 17 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition for Simmons & Simmons for European Patent No. EP3254650, dated Mar. 5, 2021, 10 pages.
3M Tegaderm, “Transparent Film Dressings,” Product Profile, filed in Opposition Proceedings for European Patent No. 2214610, mailed on Aug. 4, 2020, 8 pages.
Brief Communication—Letter from the Opponent, re the Opposition of European Patent No. 3000448, dated Apr. 21, 2021, 3 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition for Simmons & Simmons for European Patent No. 3000448, dated Apr. 23, 2021, 12 pages.
Information about the result of oral proceedings for European Patent No. 3000448, mailed on Jun. 14, 2021, 7 pages.
Interlocutory decision in Opposition proceedings (Art. 101 (3)(a) and 106(2) EPC) for European patent No. 2214611, mailed on May 20, 2021, 87 pages.
Minutes of the Oral Proceedings, Opposition Procedure and Summary of Facts and Submissions of European Patent No. 3000448, mailed on Jul. 22, 2021, 46 pages.
Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC for European Patent No. 3254650, dated Jul. 19, 2021, 13 pages.
Written Submission by the Opponent re the Opposition Proceedings for European Patent No. 2214610, mailed on Aug. 4, 2021, 2 pages.
Written Submission by the Proprietor re the Opposition Proceedings for European Patent No. 2214610, mailed on Aug. 6, 2021, 23 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition for Simmons & Simmons for European Patent No. 3360519, dated Jan. 3, 2022, 15 pages.
Decision revoking the European Patent (Art. 101 (3)(b) EPC) for European Patent No. 2214610, mailed on Nov. 15, 2021, 43 pages.
Decision to Maintain the Patent in Amended form for European Patent No. 3000448, dated Feb. 10, 2022, 1 page.
Forwarding of submissions to parties of a letter of the Opponent for European Patent No. 2214611, dated Feb. 7, 2022, 9 pages.
Information about the Result of Oral Proceedings, the Opposition of European Patent No. 2214610, dated Oct. 8, 2021, 7 pages.
Maintenance of the Patent with the Documents specified in the Final Decision, the Opposition of European Patent No. 3000448, mailed on Nov. 3, 2021, 1 page.
Notice of Opposition—Opponents' Statement of Facts and Arguments of the European Patent No. 3360519, dated Aug. 12, 2021, 12 pages.
Reply to Appeal—Letter of the patent proprietor for the European Patent No. 2214611, mailed on Jan. 24, 2022, 17 pages.
Statement of Ground of Appeal filed by Opponent for European Patent No. 2214611 mailed on Sep. 20, 2021, 3 pages.
Statement of Grounds of Appeal filed by proprietor for European patent No. 2214611, mailed on Sep. 30, 2021, 46 pages.
Termination of Opposition Proceedings for European Patent No. 3000448, dated Feb. 4, 2022, 1 page.
Thomas, Dr. S., “SMTL Dressings Datacard—Opsite IV 3000”, Surgical Materials Testing Lab, webpage last modified Mar. 2002, 2 pages. URL: http://www.dressings.org/Dressings/opsite-iv3000.html.
U.S. Appl. No. 15/457,709, Wound Dressing, filed Mar. 13, 2017.
U.S. Appl. No. 15/610,031, Wound Dressing, filed May 31, 2017.
Related Publications (1)
Number Date Country
20170181897 A1 Jun 2017 US
Continuations (3)
Number Date Country
Parent 14869826 Sep 2015 US
Child 15460123 US
Parent 14259026 Apr 2014 US
Child 14869826 US
Parent 12744277 US
Child 14259026 US